|
G |
AHR |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
epigallocatechin gallate inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl affects the localization of and results in increased activity of AHR protein]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of AHR protein]; epigallocatechin gallate inhibits the reaction [[alpha-naphthoflavone co-treated with 3,4,3',4'-tetrachlorobiphenyl] results in increased activity of AHR protein]; epigallocatechin gallate inhibits the reaction [alpha-naphthoflavone results in increased activity of AHR protein] |
CTD |
PMID:12970578 PMID:22521609 |
|
NCBI chr 9:86,511,866...86,555,950
Ensembl chr 9:86,511,369...86,555,943
|
|
G |
CCL2 |
chemokine (C-C motif) ligand 2 |
multiple interactions decreases expression |
EXP |
epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 protein]; epigallocatechin gallate inhibits the reaction [titanium dioxide results in increased expression of CCL2 mRNA]; epigallocatechin gallate inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; HMOX1 protein promotes the reaction [epigallocatechin gallate inhibits the reaction [TNF protein results in increased expression of CCL2 protein]] epigallocatechin gallate results in decreased expression of CCL2 mRNA |
CTD |
PMID:20580034 PMID:22521609 PMID:23380242 |
|
NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions decreases activity decreases expression |
EXP |
epigallocatechin gallate inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased activity of CYP1A1 protein]; epigallocatechin gallate inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 protein]; epigallocatechin gallate inhibits the reaction [beta-Naphthoflavone results in increased activity of CYP1A1 protein]; epigallocatechin gallate inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA] epigallocatechin gallate results in decreased activity of CYP1A1 protein epigallocatechin gallate results in decreased expression of CYP1A1 mRNA |
CTD |
PMID:12970578 PMID:22521609 |
|
NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,802,887...58,809,775
|
|
G |
GSTO1 |
glutathione S-transferase omega 1 |
multiple interactions increases expression |
EXP |
[epigallocatechin gallate co-treated with 3,4,5,3',4'-pentachlorobiphenyl] results in increased expression of GSTO1 mRNA; NFE2L2 protein affects the reaction [epigallocatechin gallate results in increased expression of GSTO1 mRNA] |
CTD |
PMID:22521609 |
|
NCBI chr14:115,206,434...115,216,624
Ensembl chr14:115,206,188...115,216,613
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions |
EXP |
HMOX1 protein promotes the reaction [epigallocatechin gallate inhibits the reaction [TNF protein results in increased expression of CCL2 protein]] |
CTD |
PMID:20580034 |
|
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
NFE2L2 protein affects the reaction [epigallocatechin gallate results in increased expression of GSTO1 mRNA]; NFE2L2 protein affects the reaction [epigallocatechin gallate results in increased expression of NQO1 mRNA] |
CTD |
PMID:22521609 |
|
NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
EXP |
epigallocatechin gallate results in increased expression of NQO1 mRNA [epigallocatechin gallate co-treated with 3,4,5,3',4'-pentachlorobiphenyl] results in increased expression of NQO1 mRNA; NFE2L2 protein affects the reaction [epigallocatechin gallate results in increased expression of NQO1 mRNA] |
CTD |
PMID:22521609 |
|
NCBI chr 6:17,292,962...17,302,593
Ensembl chr 6:17,292,770...17,302,590
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
multiple interactions |
EXP |
epigallocatechin gallate inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; epigallocatechin gallate inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; epigallocatechin gallate inhibits the reaction [SLCO1A2 protein results in increased uptake of Penicillins]; epigallocatechin gallate inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid] |
CTD |
PMID:31287969 |
|
NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,049,443...52,129,730
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
epigallocatechin gallate inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; HMOX1 protein promotes the reaction [epigallocatechin gallate inhibits the reaction [TNF protein results in increased expression of CCL2 protein]] |
CTD |
PMID:20580034 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
multiple interactions decreases expression |
EXP |
epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 protein]; epigallocatechin gallate inhibits the reaction [titanium dioxide results in increased expression of VCAM1 mRNA] epigallocatechin gallate results in decreased expression of VCAM1 mRNA |
CTD |
PMID:22521609 PMID:23380242 |
|
NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,920...117,511,222
|
|
|
G |
OPRM1 |
opioid receptor mu 1 |
multiple interactions |
EXP |
Enkephalin, Ala(2)-MePhe(4)-Gly(5)- inhibits the reaction [OPRM1 protein affects the reaction [Potassium results in increased abundance of Catecholamines]]; Enkephalin, Ala(2)-MePhe(4)-Gly(5)- inhibits the reaction [OPRM1 protein affects the reaction [Potassium results in increased transport of Barium]]; Enkephalin, Ala(2)-MePhe(4)-Gly(5)- inhibits the reaction [OPRM1 protein results in increased transport of Barium]; omega-Conotoxin GVIA inhibits the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- inhibits the reaction [OPRM1 protein results in increased transport of Barium]] |
CTD |
PMID:12031848 |
|
NCBI chr 1:12,634,125...12,702,295
Ensembl chr 1:12,528,672...12,702,443
|
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein] |
CTD |
PMID:24512358 |
|
NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183
|
|
|
G |
AMBP |
alpha-1-microglobulin/bikunin precursor |
decreases uptake |
EXP |
Colchicine results in decreased uptake of AMBP protein |
CTD |
PMID:9019736 |
|
NCBI chr 1:254,683,885...254,703,220
Ensembl chr 1:254,683,891...254,703,225
|
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
11-deoxyprostaglandin E1 inhibits the reaction [Ibuprofen results in decreased expression of NOS3 mRNA] |
CTD |
PMID:10525081 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions increases expression |
EXP |
16,16-Dimethylprostaglandin E2 inhibits the reaction [Ibuprofen results in decreased expression of NOS3 mRNA] 16,16-Dimethylprostaglandin E2 results in increased expression of NOS3 mRNA |
CTD |
PMID:10525081 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
|
G |
FGF7 |
fibroblast growth factor 7 |
affects expression |
EXP |
estradiol 3-benzoate affects the expression of FGF7 mRNA |
CTD |
PMID:15976484 |
|
NCBI chr 1:122,215,878...122,278,705
Ensembl chr 1:122,215,882...122,277,750
|
|
G |
FGFR2 |
fibroblast growth factor receptor 2 |
decreases expression multiple interactions |
EXP |
estradiol 3-benzoate results in decreased expression of FGFR2 mRNA alternative form [Progesterone co-treated with estradiol 3-benzoate] results in decreased expression of FGFR2 mRNA alternative form |
CTD |
PMID:15976484 |
|
NCBI chr14:131,183,095...131,285,001
Ensembl chr14:131,181,713...131,289,425
|
|
|
G |
ALOX5AP |
arachidonate 5-lipoxygenase activating protein |
multiple interactions |
EXP |
MK-886 inhibits the reaction [aristolochic acid I results in increased expression of ALOX5AP protein] |
CTD |
PMID:21658425 |
|
NCBI chr11:7,371,328...7,438,111
Ensembl chr11:7,411,644...7,438,108
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
MK-886 inhibits the reaction [aristolochic acid I results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:21658425 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression |
EXP |
oxalomalic acid results in decreased expression of BCL2 protein |
CTD |
PMID:16785314 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
oxalomalic acid promotes the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]; oxalomalic acid promotes the reaction [Cadmium results in increased cleavage of CASP3 protein] |
CTD |
PMID:16785314 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
GLRX |
glutaredoxin |
multiple interactions |
EXP |
oxalomalic acid promotes the reaction [Cadmium Chloride results in decreased activity of GLRX protein]; oxalomalic acid promotes the reaction [Cadmium results in decreased activity of GLRX protein] |
CTD |
PMID:16785314 |
|
NCBI chr 2:102,425,580...102,437,851
Ensembl chr 2:102,425,580...102,437,858
|
|
G |
IDH2 |
isocitrate dehydrogenase (NADP(+)) 2 |
decreases activity multiple interactions |
EXP |
oxalomalic acid results in decreased activity of IDH2 protein [oxalomalic acid results in decreased activity of IDH2 protein] which results in increased susceptibility to Cadmium; [oxalomalic acid results in decreased activity of IDH2 protein] which results in increased susceptibility to Cadmium Chloride |
CTD |
PMID:16785314 |
|
NCBI chr 7:55,654,298...55,675,571
Ensembl chr 7:55,651,609...55,675,554
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
oxalomalic acid promotes the reaction [Cadmium Chloride results in increased cleavage of PARP1 protein]; oxalomalic acid promotes the reaction [Cadmium results in increased cleavage of PARP1 protein] |
CTD |
PMID:16785314 |
|
NCBI chr10:14,203,157...14,241,164
Ensembl chr10:14,203,160...14,241,196
|
|
|
G |
SLC4A2 |
solute carrier family 4 member 2 |
multiple interactions |
EXP |
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid promotes the reaction [SLC4A2 protein binds to SLC4A2 protein] |
CTD |
PMID:10387099 |
|
NCBI chr18:6,149,459...6,166,622
Ensembl chr18:6,149,459...6,165,212
|
|
|
G |
ATF4 |
activating transcription factor 4 |
multiple interactions |
EXP |
4-phenylbutyric acid inhibits the reaction [Benzo(a)pyrene results in increased expression of ATF4 protein] |
CTD |
PMID:36754226 |
|
NCBI chr 5:8,742,964...8,745,752
Ensembl chr 5:8,742,967...8,745,368
|
|
G |
ATF6 |
activating transcription factor 6 |
multiple interactions |
EXP |
4-phenylbutyric acid inhibits the reaction [Benzo(a)pyrene results in increased expression of ATF6 protein] |
CTD |
PMID:36754226 |
|
NCBI chr 4:88,591,279...88,806,156
Ensembl chr 4:88,591,288...88,805,304
|
|
G |
BCL2L1 |
BCL2 like 1 |
multiple interactions |
EXP |
4-phenylbutyric acid promotes the reaction [Benzo(a)pyrene results in decreased expression of BCL2L1 protein] |
CTD |
PMID:36754226 |
|
NCBI chr17:35,366,139...35,415,798
Ensembl chr17:35,366,143...35,414,694
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
4-phenylbutyric acid inhibits the reaction [T-2 Toxin results in increased expression of CASP3 protein modified form] |
CTD |
PMID:34637808 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CLDN1 |
claudin 1 |
multiple interactions |
EXP |
4-phenylbutyric acid promotes the reaction [Benzo(a)pyrene results in decreased expression of CLDN1 protein] |
CTD |
PMID:36754226 |
|
NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657
|
|
G |
CLDN3 |
claudin 3 |
multiple interactions |
EXP |
4-phenylbutyric acid promotes the reaction [Benzo(a)pyrene results in decreased expression of CLDN3 protein] |
CTD |
PMID:36754226 |
|
NCBI chr 3:11,019,073...11,020,102
Ensembl chr 3:11,019,073...11,020,102
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
multiple interactions |
EXP |
4-phenylbutyric acid inhibits the reaction [Benzo(a)pyrene results in increased expression of DDIT3 protein] |
CTD |
PMID:36754226 |
|
NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829
|
|
G |
ERN1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
EXP |
4-phenylbutyric acid inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:36754226 |
|
NCBI chr12:14,881,913...14,963,290
Ensembl chr12:14,881,923...14,963,284
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
4-phenylbutyric acid inhibits the reaction [Benzo(a)pyrene results in increased expression of HSPA5 protein] |
CTD |
PMID:36754226 |
|
NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
|
|
G |
OCLN |
occludin |
multiple interactions |
EXP |
4-phenylbutyric acid promotes the reaction [Benzo(a)pyrene results in decreased expression of OCLN protein] |
CTD |
PMID:36754226 |
|
NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033
|
|
G |
TJP1 |
tight junction protein 1 |
multiple interactions |
EXP |
4-phenylbutyric acid promotes the reaction [Benzo(a)pyrene results in decreased expression of TJP1 protein] |
CTD |
PMID:36754226 |
|
NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836
|
|
|
G |
DAO |
D-amino acid oxidase |
decreases activity |
EXP |
5-methylpyrazole-3-carboxylic acid results in decreased activity of DAO protein |
CTD |
PMID:20952482 |
|
NCBI chr14:41,931,549...41,950,628
Ensembl chr14:41,931,541...41,950,633
|
|
|
G |
SIRT1 |
sirtuin 1 |
multiple interactions |
EXP |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in decreased expression of SIRT1 protein]] |
CTD |
PMID:36549457 |
|
NCBI chr14:71,091,167...71,126,351
Ensembl chr14:71,091,167...71,123,297
|
|
|
G |
EDN1 |
endothelin 1 |
multiple interactions |
EXP |
[15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid co-treated with EDN1 protein] results in decreased chemical synthesis of 6-Ketoprostaglandin F1 alpha |
CTD |
PMID:16325014 |
|
NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348
|
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
Aspirin inhibits the reaction [Hydrogen Peroxide results in increased expression of HSPA5 protein] |
CTD |
PMID:20665602 |
|
NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
|
|
G |
PLA2G1B |
phospholipase A2 group IB |
multiple interactions |
EXP |
Aspirin promotes the reaction [PLA2G1B protein results in increased expression of PTGS2 mRNA] |
CTD |
PMID:10706128 |
|
NCBI chr14:40,314,520...40,322,315
Ensembl chr14:40,314,520...40,322,315
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
Aspirin promotes the reaction [PLA2G1B protein results in increased expression of PTGS2 mRNA] |
CTD |
PMID:10706128 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
|
G |
PPOX |
protoporphyrinogen oxidase |
decreases activity |
EXP |
acifluorfen results in decreased activity of PPOX protein |
CTD |
PMID:7697001 |
|
NCBI chr 4:89,277,984...89,288,946
Ensembl chr 4:89,284,500...89,288,902
|
|
|
G |
GOT1 |
glutamic-oxaloacetic transaminase 1 |
affects metabolic processing decreases activity affects folding |
EXP |
Acrolein affects the metabolism of GOT1 protein Acrolein results in decreased activity of GOT1 protein Acrolein affects the folding of GOT1 protein |
CTD |
PMID:12365456 |
|
NCBI chr14:110,608,422...110,635,825
Ensembl chr14:110,608,430...110,635,874
|
|
|
G |
CALCB |
calcitonin-related polypeptide beta |
increases expression |
EXP |
Acrylamide results in increased expression of CALCA protein |
CTD |
PMID:30222996 |
|
NCBI chr 2:44,043,135...44,048,651
|
|
G |
IL6 |
interleukin 6 |
increases expression |
EXP |
Acrylamide results in increased expression of IL6 protein |
CTD |
PMID:31302221 |
|
NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
|
|
G |
LOC110258578 |
interleukin-1 beta-like |
increases expression |
EXP |
Acrylamide results in increased expression of IL1B protein |
CTD |
PMID:31302221 |
|
|
|
G |
TAC1 |
tachykinin precursor 1 |
increases expression |
EXP |
Acrylamide results in increased expression of TAC1 protein modified form |
CTD |
PMID:30222996 |
|
NCBI chr 9:77,197,403...77,206,529
Ensembl chr 9:77,197,536...77,206,523
|
|
G |
TNF |
tumor necrosis factor |
increases expression |
EXP |
Acrylamide results in increased expression of TNF protein |
CTD |
PMID:31302221 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
G |
VIP |
vasoactive intestinal peptide |
increases expression |
EXP |
Acrylamide results in increased expression of VIP protein |
CTD |
PMID:30222996 |
|
NCBI chr 1:13,611,786...13,620,250
Ensembl chr 1:13,611,311...13,620,269
|
|
|
G |
CAPN1 |
calpain 1 |
multiple interactions |
EXP |
Dactinomycin inhibits the reaction [Oxygen deficiency results in increased expression of CAPN1 mRNA] |
CTD |
PMID:9728040 |
|
NCBI chr 2:6,997,513...7,024,410
Ensembl chr 2:6,997,985...7,022,684
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Dactinomycin inhibits the reaction [Mercuric Chloride results in increased expression of FOS mRNA] |
CTD |
PMID:9463523 |
|
NCBI chr 7:98,449,508...98,451,971
Ensembl chr 7:98,449,349...98,455,554
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
Dactinomycin inhibits the reaction [Cadmium Chloride results in increased expression of HSPA5 protein]; Dactinomycin inhibits the reaction [Cadmium results in increased expression of HSPA5 protein] |
CTD |
PMID:16759985 |
|
NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
|
|
|
G |
CYP2C49 |
cytochrome P450 2C49 |
decreases response to substance |
EXP |
CYP2C49 protein results in decreased susceptibility to alachlor |
CTD |
PMID:16315095 |
|
NCBI chr14:106,571,803...106,612,082
Ensembl chr14:106,285,173...106,612,455
|
|
|
G |
AGT |
angiotensinogen |
multiple interactions increases secretion |
EXP |
3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer inhibits the reaction [AGT protein results in increased secretion of Aldosterone]; Enkephalin, D-Penicillamine (2,5)- inhibits the reaction [AGT protein results in increased secretion of Aldosterone] |
CTD |
PMID:22100847 |
|
NCBI chr14:59,643,030...59,656,835
Ensembl chr14:59,643,292...59,656,833
|
|
G |
ATP1A1 |
ATPase Na+/K+ transporting subunit alpha 1 |
increases expression |
EXP |
Aldosterone results in increased expression of ATP1A1 protein |
CTD |
PMID:28438630 |
|
NCBI chr 4:104,353,506...104,384,321
Ensembl chr 4:104,353,508...104,384,547
|
|
G |
GCLC |
glutamate-cysteine ligase catalytic subunit |
increases expression |
EXP |
Aldosterone results in increased expression of GCLC protein |
CTD |
PMID:24512358 |
|
NCBI chr 7:27,209,565...27,253,535
Ensembl chr 7:27,209,565...27,253,530
|
|
G |
HMOX1 |
heme oxygenase 1 |
increases expression |
EXP |
Aldosterone results in increased expression of HMOX1 protein |
CTD |
PMID:24512358 |
|
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]; 3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo(4,5-d)pyrimidine inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]; acetovanillone inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]; Acetylcysteine inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]; Aldosterone results in increased expression of and results in increased activity of NFE2L2 protein; diphenyleneiodonium inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]; Eplerenone inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]; Ro 32-0432 inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]; tempol inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]; Thioctic Acid inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]; W 7 inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein] |
CTD |
PMID:24512358 |
|
NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183
|
|
G |
SOD1 |
superoxide dismutase 1 |
increases expression |
EXP |
Aldosterone results in increased expression of SOD1 protein |
CTD |
PMID:24512358 |
|
NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
|
|
G |
TXNRD1 |
thioredoxin reductase 1 |
increases expression |
EXP |
Aldosterone results in increased expression of TXNRD1 protein |
CTD |
PMID:24512358 |
|
NCBI chr 5:80,170,334...80,213,889
Ensembl chr 5:80,172,260...80,236,219
|
|
|
G |
CCL2 |
chemokine (C-C motif) ligand 2 |
multiple interactions |
EXP |
Tretinoin promotes the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 protein] |
CTD |
PMID:21130106 |
|
NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026
|
|
G |
GPD1 |
glycerol-3-phosphate dehydrogenase 1 |
decreases activity |
EXP |
Tretinoin results in decreased activity of GPD1 protein |
CTD |
PMID:15583048 |
|
NCBI chr 5:16,008,179...16,021,676
Ensembl chr 5:16,007,448...16,017,825
|
|
G |
NRL |
neural retina leucine zipper |
increases expression |
EXP |
Tretinoin results in increased expression of NRL protein |
CTD |
PMID:16854989 |
|
NCBI chr 7:75,199,048...75,211,655
Ensembl chr 7:75,206,719...75,210,529
|
|
|
G |
PDIA3 |
protein disulfide isomerase family A member 3 |
increases hydrolysis |
EXP |
PDIA3 protein results in increased hydrolysis of retinol palmitate |
CTD |
PMID:16798117 |
|
NCBI chr 1:127,786,174...127,814,096
Ensembl chr 1:127,785,772...127,814,196
|
|
|
G |
INS |
insulin |
increases uptake multiple interactions |
EXP |
INS protein results in increased uptake of 2-(methylamino)isobutyric acid Dimercaprol inhibits the reaction [oxophenylarsine inhibits the reaction [INS protein results in increased uptake of 2-(methylamino)isobutyric acid]]; oxophenylarsine inhibits the reaction [INS protein results in increased uptake of 2-(methylamino)isobutyric acid] |
CTD |
PMID:1928324 |
|
NCBI chr 2:1,496,842...1,498,052
Ensembl chr 2:1,496,842...1,497,841
|
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [[Polychlorinated Biphenyls results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; alpha-Linolenic Acid inhibits the reaction [Polychlorinated Biphenyls results in increased expression of PTGS2 mRNA]; alpha-Linolenic Acid inhibits the reaction [Polychlorinated Biphenyls results in increased expression of PTGS2 protein] |
CTD |
PMID:18155686 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [Polychlorinated Biphenyls results in increased expression of VCAM1 mRNA]; alpha-Linolenic Acid inhibits the reaction [Polychlorinated Biphenyls results in increased expression of VCAM1 protein] |
CTD |
PMID:18155686 |
|
NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,920...117,511,222
|
|
|
G |
ENPEP |
glutamyl aminopeptidase |
multiple interactions |
EXP |
amastatin inhibits the reaction [ENPEP protein results in increased hydrolysis of Aspartame] |
CTD |
PMID:8141778 |
|
NCBI chr 8:111,765,839...111,858,349
Ensembl chr 8:111,748,514...111,858,510
|
|
|
G |
CLDN3 |
claudin 3 |
multiple interactions |
EXP |
Amino Acids inhibits the reaction [Diquat results in decreased expression of CLDN3 protein] |
CTD |
PMID:26338884 |
|
NCBI chr 3:11,019,073...11,020,102
Ensembl chr 3:11,019,073...11,020,102
|
|
G |
CLDN4 |
claudin 4 |
multiple interactions |
EXP |
Amino Acids inhibits the reaction [Diquat results in decreased expression of CLDN4 protein] |
CTD |
PMID:26338884 |
|
NCBI chr 3:11,039,711...11,053,930
Ensembl chr 3:11,039,706...11,053,925
|
|
G |
SLC1A1 |
solute carrier family 1 member 1 |
increases expression |
EXP |
Amino Acids results in increased expression of SLC1A1 mRNA; Amino Acids results in increased expression of SLC1A1 protein |
CTD |
PMID:26338884 |
|
NCBI chr 1:217,366,493...217,441,643
Ensembl chr 1:217,366,499...217,441,674
|
|
G |
TJP2 |
tight junction protein 2 |
multiple interactions |
EXP |
Amino Acids inhibits the reaction [Diquat results in decreased expression of TJP2 protein] |
CTD |
PMID:26338884 |
|
NCBI chr 1:222,474,518...222,612,989
Ensembl chr 1:222,474,639...222,612,983
|
|
G |
TJP3 |
tight junction protein 3 |
multiple interactions |
EXP |
Amino Acids inhibits the reaction [Diquat results in decreased expression of TJP3 protein] |
CTD |
PMID:26338884 |
|
NCBI chr 2:74,938,153...74,971,431
Ensembl chr 2:74,938,152...74,971,531
|
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
multiple interactions increases uptake |
EXP |
Amoxicillin inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Amoxicillin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid] SLCO1A2 protein results in increased uptake of Amoxicillin |
CTD |
PMID:31287969 |
|
NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,049,443...52,129,730
|
|
|
G |
AMBP |
alpha-1-microglobulin/bikunin precursor |
decreases uptake |
EXP |
Antimycin A results in decreased uptake of AMBP protein |
CTD |
PMID:9019736 |
|
NCBI chr 1:254,683,885...254,703,220
Ensembl chr 1:254,683,891...254,703,225
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
[Antimycin A co-treated with Deoxyglucose] results in increased expression of BAX protein; Quercetin inhibits the reaction [[Antimycin A co-treated with Deoxyglucose] results in increased expression of BAX protein] |
CTD |
PMID:25087994 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
MTOR |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
[Antimycin A co-treated with Deoxyglucose] results in decreased phosphorylation of MTOR protein; Quercetin promotes the reaction [[Antimycin A co-treated with Deoxyglucose] results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:25087994 |
|
NCBI chr 6:71,286,989...71,412,913
Ensembl chr 6:71,286,989...71,412,888
|
|
|
G |
ALOX5AP |
arachidonate 5-lipoxygenase activating protein |
increases expression multiple interactions |
EXP |
aristolochic acid I results in increased expression of ALOX5AP protein MK-886 inhibits the reaction [aristolochic acid I results in increased expression of ALOX5AP protein]; U 0126 inhibits the reaction [aristolochic acid I results in increased expression of ALOX5AP protein] |
CTD |
PMID:21658425 |
|
NCBI chr11:7,371,328...7,438,111
Ensembl chr11:7,411,644...7,438,108
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
aristolochic acid I results in increased cleavage of and results in increased activity of CASP3 protein; MK-886 inhibits the reaction [aristolochic acid I results in increased cleavage of and results in increased activity of CASP3 protein]; U 0126 inhibits the reaction [aristolochic acid I results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:21658425 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
LTC4S |
leukotriene C4 synthase |
decreases expression |
EXP |
aristolochic acid I results in decreased expression of LTC4S protein |
CTD |
PMID:21658425 |
|
NCBI chr 2:78,799,446...78,802,281
Ensembl chr 2:78,799,449...78,802,285
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
aristolochic acid I results in increased phosphorylation of and results in increased activity of MAPK1 protein; U 0126 inhibits the reaction [aristolochic acid I results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:21658425 |
|
NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
aristolochic acid I results in increased phosphorylation of and results in increased activity of MAPK3 protein; U 0126 inhibits the reaction [aristolochic acid I results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:21658425 |
|
NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
|
|
G |
MGST3 |
microsomal glutathione S-transferase 3 |
increases expression multiple interactions |
EXP |
aristolochic acid I results in increased expression of MGST3 protein U 0126 inhibits the reaction [aristolochic acid I results in increased expression of MGST3 protein] |
CTD |
PMID:21658425 |
|
NCBI chr 4:85,069,603...85,095,022
Ensembl chr 4:85,069,607...85,094,981
|
|
|
G |
FABP4 |
fatty acid binding protein 4 |
decreases expression |
EXP |
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid results in decreased expression of FABP4 mRNA |
CTD |
PMID:15583048 |
|
NCBI chr 4:55,096,400...55,101,209
Ensembl chr 4:55,096,404...55,101,896
|
|
G |
GPD1 |
glycerol-3-phosphate dehydrogenase 1 |
decreases activity |
EXP |
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid results in decreased activity of GPD1 protein |
CTD |
PMID:15583048 |
|
NCBI chr 5:16,008,179...16,021,676
Ensembl chr 5:16,007,448...16,017,825
|
|
G |
NR2F1 |
nuclear receptor subfamily 2 group F member 1 |
increases expression |
EXP |
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid results in increased expression of NR2F1 mRNA |
CTD |
PMID:15583048 |
|
NCBI chr 2:100,447,661...100,457,510
Ensembl chr 2:100,447,705...100,457,506
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
decreases expression |
EXP |
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid results in decreased expression of PPARG mRNA |
CTD |
PMID:15583048 |
|
NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,322...68,433,944
|
|
G |
RXRA |
retinoid X receptor alpha |
decreases expression |
EXP |
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid results in decreased expression of RXRA mRNA |
CTD |
PMID:15583048 |
|
NCBI chr 1:273,698,842...273,797,622
Ensembl chr 1:273,705,505...273,797,620
|
|
G |
SREBP-1 |
sterol regulatory element binding protein 1 |
decreases expression |
EXP |
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid results in decreased expression of SREBP-1 mRNA |
CTD |
PMID:15583048 |
|
|
|
|
G |
ENPEP |
glutamyl aminopeptidase |
multiple interactions increases hydrolysis |
EXP |
1,10-phenanthroline inhibits the reaction [ENPEP protein results in increased hydrolysis of Aspartame]; amastatin inhibits the reaction [ENPEP protein results in increased hydrolysis of Aspartame]; Calcium Chloride promotes the reaction [ENPEP protein results in increased hydrolysis of Aspartame] |
CTD |
PMID:8141778 |
|
NCBI chr 8:111,765,839...111,858,349
Ensembl chr 8:111,748,514...111,858,510
|
|
|
G |
MYL9 |
myosin light chain 9 |
multiple interactions |
EXP |
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [calyculin A results in increased phosphorylation of MYL9 protein]]; [Calcium co-treated with 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid] results in decreased phosphorylation of MYL9 protein |
CTD |
PMID:10942722 |
|
NCBI chr17:39,788,165...39,795,240
Ensembl chr17:39,788,199...39,795,293
|
|
|
G |
ABCB1 |
ATP-binding cassette, sub-family B (MDR/TAP), member 1 |
increases expression decreases activity |
EXP |
beauvericin results in increased expression of ABCB1 mRNA beauvericin results in decreased activity of ABCB1 protein |
CTD |
PMID:27474255 |
|
NCBI chr 9:93,049,955...93,146,469
|
|
G |
CYP11A1 |
cytochrome P450 family 11 subfamily A member 1 |
increases expression |
EXP |
beauvericin results in increased expression of CYP11A1 mRNA |
CTD |
PMID:27474255 |
|
NCBI chr 7:59,172,829...59,188,479
Ensembl chr 7:59,175,758...59,188,478
|
|
G |
MT-CO1 |
mitochondrially encoded cytochrome c oxidase I |
increases expression |
EXP |
beauvericin results in increased expression of COX1 mRNA |
CTD |
PMID:27474255 |
|
NCBI chr MT:6,511...8,055
Ensembl chr MT:6,511...8,055
|
|
|
G |
GSDMD |
gasdermin D |
multiple interactions |
EXP |
belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of GSDMD mRNA]; belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of GSDMD protein] |
CTD |
PMID:36309173 |
|
NCBI chr 4:995,753...1,001,964
Ensembl chr 4:995,763...1,000,271
|
|
G |
IL18 |
interleukin 18 |
multiple interactions |
EXP |
belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL18 mRNA]; belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL18 protein] |
CTD |
PMID:36309173 |
|
NCBI chr 9:39,839,959...39,861,258
Ensembl chr 9:39,834,973...39,861,219
|
|
G |
LOC110258578 |
interleukin-1 beta-like |
multiple interactions |
EXP |
belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL1B mRNA]; belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL1B protein] |
CTD |
PMID:36309173 |
|
|
|
|
G |
KNG1 |
kininogen 1 |
increases activity |
EXP |
benazepril results in increased activity of KNG1 protein modified form |
CTD |
PMID:7890486 |
|
NCBI chr13:124,521,276...124,557,384
Ensembl chr13:124,521,340...124,557,958
|
|
|
G |
SLC9A1 |
solute carrier family 9 member A1 |
decreases activity |
EXP |
benzamide analog results in decreased activity of SLC9A1 protein |
CTD |
PMID:17724433 |
|
NCBI chr 6:84,373,921...84,426,447
Ensembl chr 6:84,372,649...84,426,997
|
|
|
G |
MOCOS |
molybdenum cofactor sulfurase |
affects reduction |
EXP |
MOCOS protein affects the reduction of benzamidoxime |
CTD |
PMID:16973608 |
|
NCBI chr 6:119,945,076...120,018,332
Ensembl chr 6:119,945,052...120,018,097
|
|
|
G |
APOA1 |
apolipoprotein A1 |
increases expression increases secretion |
EXP |
Bezafibrate results in increased expression of APOA1 mRNA Bezafibrate results in increased secretion of APOA1 protein |
CTD |
PMID:16530456 |
|
NCBI chr 9:44,216,481...44,218,360
Ensembl chr 9:44,216,392...44,218,713
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Bezafibrate inhibits the reaction [Cisplatin affects the localization of BAX protein] |
CTD |
PMID:16316343 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
increases expression |
EXP |
Bezafibrate results in increased expression of BCL2 |
CTD |
PMID:16316343 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
Bezafibrate inhibits the reaction [Cisplatin results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:16316343 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CYCS |
cytochrome c, somatic |
multiple interactions |
EXP |
Bezafibrate inhibits the reaction [Cisplatin affects the localization of CYCS protein] |
CTD |
PMID:16316343 |
|
NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
|
|
G |
LIPG |
lipase G, endothelial type |
decreases expression |
EXP |
Bezafibrate results in decreased expression of LIPG mRNA; Bezafibrate results in decreased expression of LIPG protein |
CTD |
PMID:15953354 |
|
NCBI chr 1:99,081,940...99,110,671
Ensembl chr 1:99,081,938...99,110,874
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
Bezafibrate inhibits the reaction [[Cisplatin results in decreased activity of PPARA protein] which results in increased abundance of Fatty Acids, Nonesterified]; Bezafibrate inhibits the reaction [Cisplatin results in decreased activity of PPARA protein] |
CTD |
PMID:16316343 |
|
NCBI chr 5:3,302,755...3,321,091
Ensembl chr 5:3,300,741...3,364,239
|
|
G |
SCARB1 |
scavenger receptor class B member 1 |
affects localization increases expression |
EXP |
Bezafibrate affects the localization of SCARB1 protein Bezafibrate results in increased expression of SCARB1 mRNA |
CTD |
PMID:16530456 |
|
NCBI chr14:28,301,421...28,393,568
Ensembl chr14:28,301,294...28,393,568
|
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
affects phosphorylation |
EXP |
bifenthrin affects the phosphorylation of AKT1 protein |
CTD |
PMID:33901951 |
|
|
|
G |
CCL14 |
C-C motif chemokine ligand 14 |
decreases expression |
EXP |
bifenthrin results in decreased expression of CCL14 mRNA |
CTD |
PMID:33901951 |
|
NCBI chr12:39,611,887...39,616,050
Ensembl chr12:39,611,868...39,616,159
|
|
G |
CCL4 |
C-C motif chemokine ligand 4 |
decreases expression |
EXP |
bifenthrin results in decreased expression of CCL4 mRNA |
CTD |
PMID:33901951 |
|
NCBI chr12:39,479,190...39,480,511
Ensembl chr12:39,478,882...39,481,082
|
|
G |
CCND1 |
cyclin D1 |
decreases expression |
EXP |
bifenthrin results in decreased expression of CCND1 mRNA |
CTD |
PMID:33901951 |
|
NCBI chr 2:3,621,242...3,633,380
Ensembl chr 2:3,621,246...3,633,296
|
|
G |
CCNE1 |
cyclin E1 |
decreases expression |
EXP |
bifenthrin results in decreased expression of CCNE1 mRNA |
CTD |
PMID:33901951 |
|
NCBI chr 6:39,919,541...39,933,224
Ensembl chr 6:39,919,624...39,933,366
|
|
G |
CX3CL1 |
C-X3-C motif chemokine ligand 1 |
decreases expression |
EXP |
bifenthrin results in decreased expression of CX3CL1 mRNA |
CTD |
PMID:33901951 |
|
NCBI chr 6:19,312,351...19,324,439
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
increases expression |
EXP |
bifenthrin results in increased expression of DDIT3 protein |
CTD |
PMID:33901951 |
|
NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829
|
|
G |
EIF2S1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation |
EXP |
bifenthrin results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:33901951 |
|
NCBI chr 7:91,085,025...91,109,835
Ensembl chr 7:91,085,335...91,109,827
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
EXP |
bifenthrin results in increased expression of HSPA5 protein |
CTD |
PMID:33901951 |
|
NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
|
|
G |
LEPR |
leptin receptor |
decreases expression |
EXP |
bifenthrin results in decreased expression of LEPR mRNA |
CTD |
PMID:33901951 |
|
NCBI chr 6:146,802,297...146,896,152
Ensembl chr 6:146,801,954...146,895,995
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
increases phosphorylation |
EXP |
bifenthrin results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:33901951 |
|
NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
increases phosphorylation |
EXP |
bifenthrin results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:33901951 |
|
NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
increases phosphorylation |
EXP |
bifenthrin results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:33901951 |
|
NCBI chr14:88,988,914...89,108,875
Ensembl chr14:88,988,949...89,108,874
|
|
G |
PCNA |
proliferating cell nuclear antigen |
decreases expression |
EXP |
bifenthrin results in decreased expression of PCNA protein |
CTD |
PMID:33901951 |
|
NCBI chr17:14,137,746...14,142,584
Ensembl chr17:14,136,886...14,142,744
|
|
G |
RARB |
retinoic acid receptor beta |
decreases expression |
EXP |
bifenthrin results in decreased expression of RARB mRNA |
CTD |
PMID:33901951 |
|
NCBI chr13:12,336,387...12,507,688
Ensembl chr13:12,336,972...12,507,680
|
|
G |
RPS6 |
ribosomal protein S6 |
increases phosphorylation |
EXP |
bifenthrin results in increased phosphorylation of RPS6 protein |
CTD |
PMID:33901951 |
|
NCBI chr 1:203,444,360...203,447,643
Ensembl chr 1:203,444,450...203,451,468
|
|
G |
RPS6KB1 |
ribosomal protein S6 kinase B1 |
affects phosphorylation |
EXP |
bifenthrin affects the phosphorylation of RPS6KB1 protein |
CTD |
PMID:33901951 |
|
NCBI chr12:36,111,584...36,159,287
Ensembl chr12:36,111,653...36,160,376
|
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
Bilirubin inhibits the reaction [Excitatory Amino Acid Agents results in increased activity of CASP3 protein] |
CTD |
PMID:16371440 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
GH1 |
growth hormone 1 |
multiple interactions |
EXP |
GH1 protein inhibits the reaction [Lipopolysaccharides results in increased abundance of Bilirubin] |
CTD |
PMID:9185964 |
|
NCBI chr12:15,064,965...15,066,698
Ensembl chr12:15,064,909...15,066,696
|
|
|
G |
ATP1A1 |
ATPase Na+/K+ transporting subunit alpha 1 |
increases expression |
EXP |
Bucladesine results in increased expression of ATP1A1 protein |
CTD |
PMID:28438630 |
|
NCBI chr 4:104,353,506...104,384,321
Ensembl chr 4:104,353,508...104,384,547
|
|
|
G |
ADCYAP1 |
adenylate cyclase activating polypeptide 1 |
multiple interactions |
EXP |
Capsaicin inhibits the reaction [ADCYAP1 protein alternative form results in decreased susceptibility to 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid] |
CTD |
PMID:14662737 |
|
NCBI chr 6:105,414,628...105,422,294
Ensembl chr 6:105,414,631...105,422,294
|
|
G |
TAC1 |
tachykinin precursor 1 |
increases secretion |
EXP |
Capsaicin results in increased secretion of TAC1 protein |
CTD |
PMID:10766449 |
|
NCBI chr 9:77,197,403...77,206,529
Ensembl chr 9:77,197,536...77,206,523
|
|
|
G |
CAT |
catalase |
decreases activity |
EXP |
Cephaloridine results in decreased activity of CAT protein |
CTD |
PMID:11039594 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
|
G |
ACHE |
acetylcholinesterase |
increases activity |
EXP |
Chenodeoxycholic Acid results in increased activity of ACHE protein |
CTD |
PMID:3697337 |
|
NCBI chr 3:8,732,451...8,738,274
Ensembl chr 3:8,732,441...8,738,605
|
|
G |
LRP2 |
LDL receptor related protein 2 |
increases expression |
EXP |
Chenodeoxycholic Acid results in increased expression of LRP2 protein |
CTD |
PMID:15375181 |
|
NCBI chr15:75,565,299...75,754,604
Ensembl chr15:75,565,303...75,716,694
|
|
|
G |
COMT |
catechol-O-methyltransferase |
decreases activity |
EXP |
Chlorogenic Acid results in decreased activity of COMT protein |
CTD |
PMID:27270453 |
|
NCBI chr14:51,384,729...51,403,997
Ensembl chr14:51,385,738...51,403,998
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CXCL8 protein]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 mRNA] |
CTD |
PMID:27861533 |
|
NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:27861533 |
|
NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:27861533 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:27861533 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
|
G |
CYP2B6B |
cytochrome P450 family 2 subfamily B member 6B |
decreases response to substance |
EXP |
CYP2B6B protein results in decreased susceptibility to chlortoluron |
CTD |
PMID:16315095 |
|
NCBI chr 6:49,158,175...49,173,872
Ensembl chr 6:49,110,812...49,178,334
|
|
G |
CYP2C49 |
cytochrome P450 2C49 |
decreases response to substance |
EXP |
CYP2C49 protein results in decreased susceptibility to chlortoluron |
CTD |
PMID:16315095 |
|
NCBI chr14:106,571,803...106,612,082
Ensembl chr14:106,285,173...106,612,455
|
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
multiple interactions increases uptake |
EXP |
Chlortetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; daidzein inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; epigallocatechin gallate inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; Genistein inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; naringin inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; Oxytetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline] |
CTD |
PMID:31287969 |
|
NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,049,443...52,129,730
|
|
|
G |
ACHE |
acetylcholinesterase |
increases activity |
EXP |
Cholic Acid results in increased activity of ACHE protein |
CTD |
PMID:3697337 |
|
NCBI chr 3:8,732,451...8,738,274
Ensembl chr 3:8,732,441...8,738,605
|
|
G |
LRP2 |
LDL receptor related protein 2 |
increases expression |
EXP |
Cholic Acid results in increased expression of LRP2 protein |
CTD |
PMID:15375181 |
|
NCBI chr15:75,565,299...75,754,604
Ensembl chr15:75,565,303...75,716,694
|
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
Cilastatin inhibits the reaction [Cisplatin results in increased activity of CASP3 protein] |
CTD |
PMID:20435919 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CASP8 |
caspase 8 |
multiple interactions |
EXP |
Cilastatin inhibits the reaction [Cisplatin results in increased activity of CASP8 protein] |
CTD |
PMID:20435919 |
|
NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468
|
|
G |
FASLG |
Fas ligand |
multiple interactions |
EXP |
Cilastatin inhibits the reaction [Cisplatin affects the localization of FASLG protein] |
CTD |
PMID:20435919 |
|
NCBI chr 9:115,068,314...115,075,147
Ensembl chr 9:115,068,090...115,076,464
|
|
|
G |
GUCY1A1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions |
EXP |
BAY 58-2667 inhibits the reaction [1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one results in increased degradation of GUCY1A1 protein] |
CTD |
PMID:19466990 |
|
NCBI chr 8:44,448,758...44,520,737
Ensembl chr 8:44,449,290...44,518,135
|
|
G |
GUCY1B1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
EXP |
BAY 58-2667 inhibits the reaction [1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one results in increased degradation of GUCY1B1 protein] |
CTD |
PMID:19466990 |
|
NCBI chr 8:44,544,364...44,604,690
Ensembl chr 8:44,544,179...44,604,687
|
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
[ciprofibrate co-treated with Zinc] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased activity of TNF protein] |
CTD |
PMID:15226458 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
|
G |
ACO1 |
aconitase 1 |
increases expression |
EXP |
Clofibrate results in increased expression of ACO1 mRNA |
CTD |
PMID:17363680 |
|
NCBI chr10:33,937,833...34,001,895
Ensembl chr10:33,937,833...34,001,900
|
|
G |
ACOX1 |
acyl-CoA oxidase 1 |
increases expression |
EXP |
Clofibrate results in increased expression of ACOX1 mRNA |
CTD |
PMID:16896063 PMID:17437637 |
|
NCBI chr12:5,450,913...5,479,550
Ensembl chr12:5,439,361...5,479,546
|
|
G |
AGT |
angiotensinogen |
multiple interactions |
EXP |
Clofibrate inhibits the reaction [AGT protein modified form results in increased expression of EDN1 protein] |
CTD |
PMID:17105827 |
|
NCBI chr14:59,643,030...59,656,835
Ensembl chr14:59,643,292...59,656,833
|
|
G |
ALB |
albumin |
decreases expression |
EXP |
Clofibrate results in decreased expression of ALB mRNA |
CTD |
PMID:16896063 |
|
NCBI chr 8:69,643,427...69,663,152
Ensembl chr 8:69,531,487...69,721,696
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
Clofibrate results in increased expression of BAX mRNA |
CTD |
PMID:17437637 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
BCL2L1 |
BCL2 like 1 |
decreases expression |
EXP |
Clofibrate results in decreased expression of BCL2L1 mRNA |
CTD |
PMID:17437637 |
|
NCBI chr17:35,366,139...35,415,798
Ensembl chr17:35,366,143...35,414,694
|
|
G |
CAT |
catalase |
increases expression |
EXP |
Clofibrate results in increased expression of CAT mRNA |
CTD |
PMID:17437637 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
CPT1A |
carnitine palmitoyltransferase 1A |
increases expression |
EXP |
Clofibrate results in increased expression of CPT1A mRNA |
CTD |
PMID:16896063 PMID:17363680 |
|
NCBI chr 2:4,250,642...4,293,914
Ensembl chr 2:4,233,099...4,293,911
|
|
G |
CTSB |
cathepsin B |
increases expression |
EXP |
Clofibrate results in increased expression of CTSB mRNA |
CTD |
PMID:16896063 |
|
NCBI chr14:15,014,139...15,035,081
Ensembl chr14:15,011,711...15,033,877
|
|
G |
DIO2 |
iodothyronine deiodinase 2 |
decreases expression |
EXP |
Clofibrate results in decreased expression of DIO2 mRNA |
CTD |
PMID:16896063 |
|
NCBI chr 7:103,096,414...103,110,749
Ensembl chr 7:103,096,433...103,323,258
|
|
G |
EDN1 |
endothelin 1 |
decreases expression multiple interactions |
EXP |
Clofibrate results in decreased expression of EDN1 protein Clofibrate inhibits the reaction [AGT protein modified form results in increased expression of EDN1 protein]; Clofibrate inhibits the reaction [KNG1 protein modified form results in increased expression of EDN1 protein]; Clofibrate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EDN1 protein]; Nitric Oxide deficiency inhibits the reaction [Clofibrate results in decreased expression of EDN1 protein] |
CTD |
PMID:17105827 |
|
NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348
|
|
G |
FABP1 |
fatty acid binding protein 1 |
increases expression |
EXP |
Clofibrate results in increased expression of FABP1 mRNA |
CTD |
PMID:17363680 |
|
NCBI chr 3:57,850,511...57,854,966
Ensembl chr 3:57,850,499...57,854,956
|
|
G |
GPX1 |
glutathione peroxidase 1 |
decreases expression |
EXP |
Clofibrate results in decreased expression of GPX1 mRNA |
CTD |
PMID:17437637 |
|
NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
|
|
G |
HMGCS2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
increases expression |
EXP |
Clofibrate results in increased expression of HMGCS2 mRNA |
CTD |
PMID:17363680 |
|
NCBI chr 4:101,420,941...101,440,302
Ensembl chr 4:101,420,872...101,438,126
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Clofibrate results in increased expression of JUN mRNA |
CTD |
PMID:17437637 |
|
NCBI chr 6:153,686,425...153,687,635
Ensembl chr 6:153,685,682...153,687,636
|
|
G |
KNG1 |
kininogen 1 |
multiple interactions |
EXP |
Clofibrate inhibits the reaction [KNG1 protein modified form results in increased expression of EDN1 protein] |
CTD |
PMID:17105827 |
|
NCBI chr13:124,521,276...124,557,384
Ensembl chr13:124,521,340...124,557,958
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
EXP |
Clofibrate results in increased expression of MYC mRNA |
CTD |
PMID:17437637 |
|
NCBI chr 4:12,455,141...12,460,360
Ensembl chr 4:12,455,122...12,461,078
|
|
G |
NOS3 |
nitric oxide synthase 3 |
increases expression multiple interactions |
EXP |
Clofibrate results in increased expression of NOS3 protein calphostin C inhibits the reaction [Clofibrate results in increased expression of NOS3 protein] |
CTD |
PMID:17105827 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
increases expression multiple interactions |
EXP |
Clofibrate results in increased expression of PPARA; Clofibrate results in increased expression of PPARA protein calphostin C inhibits the reaction [Clofibrate results in increased expression of PPARA protein]; calphostin C inhibits the reaction [Clofibrate results in increased expression of PPARA]; Tetradecanoylphorbol Acetate inhibits the reaction [Clofibrate results in increased expression of PPARA] |
CTD |
PMID:17105827 PMID:20568414 |
|
NCBI chr 5:3,302,755...3,321,091
Ensembl chr 5:3,300,741...3,364,239
|
|
G |
SCD |
stearoyl-CoA desaturase |
increases expression |
EXP |
Clofibrate results in increased expression of SCD mRNA |
CTD |
PMID:17363680 |
|
NCBI chr14:111,461,560...111,478,033
Ensembl chr14:111,461,569...111,478,020
|
|
G |
SLC5A5 |
solute carrier family 5 member 5 |
increases expression |
EXP |
Clofibrate results in increased expression of SLC5A5 mRNA |
CTD |
PMID:16896063 |
|
NCBI chr 2:59,869,157...59,885,086
Ensembl chr 2:59,869,155...59,885,266
|
|
G |
SOD1 |
superoxide dismutase 1 |
increases expression |
EXP |
Clofibrate results in increased expression of SOD1 mRNA |
CTD |
PMID:17437637 |
|
NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
|
|
G |
THRA |
thyroid hormone receptor alpha |
decreases expression |
EXP |
Clofibrate results in decreased expression of THRA mRNA |
CTD |
PMID:16896063 |
|
NCBI chr12:22,270,506...22,296,684
Ensembl chr12:22,270,062...22,296,618
|
|
G |
TNF |
tumor necrosis factor |
decreases expression |
EXP |
Clofibrate results in decreased expression of TNF mRNA |
CTD |
PMID:17437637 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
G |
TPO |
thyroid peroxidase |
increases expression |
EXP |
Clofibrate results in increased expression of TPO mRNA |
CTD |
PMID:16896063 |
|
NCBI chr 3:132,384,677...132,409,750
Ensembl chr 3:132,384,583...132,409,208
|
|
G |
TSHR |
thyroid stimulating hormone receptor |
increases expression |
EXP |
Clofibrate results in increased expression of TSHR mRNA |
CTD |
PMID:16896063 |
|
NCBI chr 7:103,768,260...103,925,777
Ensembl chr 7:103,768,296...103,925,922
|
|
G |
TTR |
transthyretin |
decreases expression |
EXP |
Clofibrate results in decreased expression of TTR mRNA |
CTD |
PMID:16896063 |
|
NCBI chr 6:115,496,338...115,503,974
Ensembl chr 6:115,496,326...115,503,977
|
|
|
G |
HSD3B1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
increases expression |
EXP |
Cloprostenol results in increased expression of HSD3B1 mRNA |
CTD |
PMID:15713365 |
|
NCBI chr 4:101,565,229...101,574,110
|
|
G |
LDLR |
low density lipoprotein receptor |
decreases expression |
EXP |
Cloprostenol results in decreased expression of LDLR mRNA |
CTD |
PMID:15713365 |
|
NCBI chr 2:69,828,348...69,864,823
Ensembl chr 2:69,828,332...69,864,827
|
|
G |
LHCGR |
luteinizing hormone/choriogonadotropin receptor |
decreases expression |
EXP |
Cloprostenol results in decreased expression of LHCGR mRNA; Cloprostenol results in decreased expression of LHCGR protein |
CTD |
PMID:15713365 |
|
NCBI chr 3:91,964,415...92,023,821
Ensembl chr 3:91,964,415...92,021,398
|
|
G |
NR0B1 |
nuclear receptor subfamily 0 group B member 1 |
increases expression |
EXP |
Cloprostenol results in increased expression of NR0B1 mRNA |
CTD |
PMID:15713365 |
|
NCBI chr X:26,117,874...26,122,951
Ensembl chr X:26,117,874...26,122,951
|
|
G |
STAR |
steroidogenic acute regulatory protein |
decreases expression |
EXP |
Cloprostenol results in decreased expression of STAR mRNA; Cloprostenol results in decreased expression of STAR protein |
CTD |
PMID:15713365 |
|
NCBI chr15:48,377,597...48,385,398
Ensembl chr15:48,377,521...48,385,462
|
|
|
G |
EDN1 |
endothelin 1 |
increases expression multiple interactions |
EXP |
Cocaine results in increased expression of EDN1 protein 1,3-ditolylguanidine inhibits the reaction [Cocaine results in increased expression of EDN1 protein]; Haloperidol inhibits the reaction [Cocaine results in increased expression of EDN1 protein] |
CTD |
PMID:9714087 |
|
NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348
|
|
|
G |
ACO2 |
aconitase 2 |
multiple interactions |
EXP |
Curcumin inhibits the reaction [maleic acid results in decreased activity of ACO2 protein] |
CTD |
PMID:25119790 |
|
NCBI chr 5:7,014,383...7,071,023
Ensembl chr 5:7,008,719...7,071,025
|
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions affects localization |
EXP |
Vitamin E inhibits the reaction [Cyclosporine affects the localization of BAX protein] |
CTD |
PMID:19523970 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
CASP6 |
caspase 6 |
multiple interactions increases expression |
EXP |
Vitamin E inhibits the reaction [Cyclosporine results in increased expression of CASP6 mRNA] |
CTD |
PMID:19523970 |
|
NCBI chr 8:112,519,450...112,534,315
Ensembl chr 8:112,520,629...112,537,045
|
|
G |
CYCS |
cytochrome c, somatic |
multiple interactions affects localization |
EXP |
Vitamin E inhibits the reaction [Cyclosporine affects the localization of CYCS protein] |
CTD |
PMID:23347876 |
|
NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
|
|
G |
EDN1 |
endothelin 1 |
increases secretion |
EXP |
Cyclosporine results in increased secretion of EDN1 protein |
CTD |
PMID:16391421 |
|
NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348
|
|
G |
FGD4 |
FYVE, RhoGEF and PH domain containing 4 |
multiple interactions increases expression |
EXP |
Vitamin E inhibits the reaction [Cyclosporine results in increased expression of DNM1L protein] |
CTD |
PMID:23347876 |
|
NCBI chr 5:41,571,054...41,636,058
Ensembl chr 5:41,570,282...41,636,028
|
|
G |
MFN2 |
mitofusin 2 |
multiple interactions decreases expression |
EXP |
Vitamin E inhibits the reaction [Cyclosporine results in decreased expression of MFN2 protein] |
CTD |
PMID:23347876 |
|
NCBI chr 6:72,026,512...72,056,439
Ensembl chr 6:72,028,499...72,056,438
|
|
G |
NOS3 |
nitric oxide synthase 3 |
decreases expression |
EXP |
Cyclosporine results in decreased expression of NOS3 protein |
CTD |
PMID:12695417 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
G |
OPA1 |
OPA1 mitochondrial dynamin like GTPase |
decreases expression multiple interactions |
EXP |
Cyclosporine results in decreased expression of OPA1 protein Vitamin E inhibits the reaction [Cyclosporine results in decreased expression of OPA1 protein] |
CTD |
PMID:23347876 |
|
NCBI chr13:130,624,771...130,718,345
Ensembl chr13:130,624,796...130,719,083
|
|
G |
RAC1 |
Rac family small GTPase 1 |
affects localization |
EXP |
Cyclosporine affects the localization of RAC1 protein |
CTD |
PMID:12695417 |
|
NCBI chr 3:4,781,776...4,803,510
Ensembl chr 3:4,781,780...4,803,543
|
|
G |
SLC2A1 |
solute carrier family 2 member 1 |
decreases response to substance multiple interactions increases expression |
EXP |
SLC2A1 protein results in decreased susceptibility to Cyclosporine Amiloride promotes the reaction [Cyclosporine results in increased expression of SLC2A1 mRNA]; Phloretin promotes the reaction [Cyclosporine results in increased expression of SLC2A1 mRNA]; Phloretin promotes the reaction [Cyclosporine results in increased expression of SLC2A1 protein] Cyclosporine results in increased expression of SLC2A1 mRNA; Cyclosporine results in increased expression of SLC2A1 protein |
CTD |
PMID:12081571 |
|
NCBI chr 6:168,535,398...168,561,170
Ensembl chr 6:168,535,440...168,560,867
|
|
|
G |
ACHE |
acetylcholinesterase |
increases activity |
EXP |
Deoxycholic Acid results in increased activity of ACHE protein |
CTD |
PMID:3697337 |
|
NCBI chr 3:8,732,451...8,738,274
Ensembl chr 3:8,732,441...8,738,605
|
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
increases expression |
EXP |
Deferoxamine results in increased expression of HIF1A protein |
CTD |
PMID:11514583 PMID:15089098 |
|
NCBI chr 1:190,625,436...190,673,926
Ensembl chr 1:190,625,244...190,674,845
|
|
|
G |
PRDX2 |
peroxiredoxin 2 |
decreases activity |
EXP |
diethyl maleate results in decreased activity of PRDX2 protein |
CTD |
PMID:19208552 |
|
NCBI chr 2:66,207,829...66,211,474
Ensembl chr 2:66,207,828...66,212,009
|
|
|
G |
AGT |
angiotensinogen |
multiple interactions |
EXP |
Enkephalin, D-Penicillamine (2,5)- inhibits the reaction [AGT protein results in increased secretion of Aldosterone] |
CTD |
PMID:22100847 |
|
NCBI chr14:59,643,030...59,656,835
Ensembl chr14:59,643,292...59,656,833
|
|
G |
OPRD1 |
opioid receptor delta 1 |
multiple interactions |
EXP |
Enkephalin, D-Penicillamine (2,5)- inhibits the reaction [OPRD1 protein results in increased transport of Barium] |
CTD |
PMID:12031848 |
|
NCBI chr 6:85,775,576...85,827,170
Ensembl chr 6:85,785,276...85,830,877
|
|
|
G |
AGT |
angiotensinogen |
affects activity |
EXP |
Enalapril affects the activity of AGT protein |
CTD |
PMID:21127344 |
|
NCBI chr14:59,643,030...59,656,835
Ensembl chr14:59,643,292...59,656,833
|
|
|
G |
AGT |
angiotensinogen |
decreases activity |
EXP |
Enalaprilat results in decreased activity of AGT protein modified form |
CTD |
PMID:7890486 |
|
NCBI chr14:59,643,030...59,656,835
Ensembl chr14:59,643,292...59,656,833
|
|
G |
KNG1 |
kininogen 1 |
increases activity |
EXP |
Enalaprilat results in increased activity of KNG1 protein modified form |
CTD |
PMID:7890486 |
|
NCBI chr13:124,521,276...124,557,384
Ensembl chr13:124,521,340...124,557,958
|
|
|
G |
ANPEP |
alanyl aminopeptidase, membrane |
multiple interactions |
EXP |
Edetic Acid promotes the reaction [1,10-phenanthroline results in decreased activity of ANPEP protein] |
CTD |
PMID:17109655 |
|
NCBI chr 7:55,351,081...55,373,856
Ensembl chr 7:55,351,087...55,373,881
|
|
G |
LTA4H |
leukotriene A4 hydrolase |
decreases activity |
EXP |
Edetic Acid results in decreased activity of LTA4H protein |
CTD |
PMID:21670530 |
|
NCBI chr 5:87,486,552...87,518,520
Ensembl chr 5:87,486,512...87,518,515
|
|
|
G |
HMGCR |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions increases expression |
EXP |
Simvastatin promotes the reaction [Ezetimibe results in increased expression of HMGCR mRNA] |
CTD |
PMID:17130282 |
|
NCBI chr 2:84,380,245...84,401,117
Ensembl chr 2:84,380,224...84,402,957
|
|
G |
LDLR |
low density lipoprotein receptor |
increases expression multiple interactions |
EXP |
Ezetimibe results in increased expression of LDLR mRNA Simvastatin promotes the reaction [Ezetimibe results in increased expression of LDLR mRNA] |
CTD |
PMID:17130282 |
|
NCBI chr 2:69,828,348...69,864,823
Ensembl chr 2:69,828,332...69,864,827
|
|
G |
NPC1L1 |
NPC1 like intracellular cholesterol transporter 1 |
multiple interactions increases expression |
EXP |
Simvastatin promotes the reaction [Ezetimibe results in increased expression of NPC1L1 mRNA] |
CTD |
PMID:17130282 |
|
NCBI chr18:50,726,854...50,757,676
Ensembl chr18:50,726,922...50,757,649
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
[Ezetimibe co-treated with Simvastatin] results in increased expression of SREBF1 mRNA |
CTD |
PMID:17130282 |
|
NCBI chr12:60,733,967...60,750,951
Ensembl chr12:60,733,907...60,751,267
|
|
G |
SREBF2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions increases expression |
EXP |
Simvastatin promotes the reaction [Ezetimibe results in increased expression of SREBF2 mRNA] |
CTD |
PMID:17130282 |
|
NCBI chr 5:6,719,484...6,784,724
Ensembl chr 5:6,719,490...6,784,671
|
|
|
G |
ABCA1 |
ATP binding cassette subfamily A member 1 |
affects localization |
EXP |
Fenofibrate affects the localization of ABCA1 protein |
CTD |
PMID:16530456 |
|
NCBI chr 1:246,144,277...246,278,492
Ensembl chr 1:246,144,277...246,278,492
|
|
G |
APOA1 |
apolipoprotein A1 |
increases secretion decreases expression multiple interactions |
EXP |
Fenofibrate results in increased secretion of APOA1 protein Fenofibrate results in decreased expression of APOA1 mRNA Fenofibrate inhibits the reaction [APOA1 protein results in increased transport of Cholesterol]; Fenofibrate promotes the reaction [APOA1 protein results in increased transport of Cholesterol] |
CTD |
PMID:16530456 |
|
NCBI chr 9:44,216,481...44,218,360
Ensembl chr 9:44,216,392...44,218,713
|
|
G |
SCARB1 |
scavenger receptor class B member 1 |
affects localization |
EXP |
Fenofibrate affects the localization of SCARB1 protein |
CTD |
PMID:16530456 |
|
NCBI chr14:28,301,421...28,393,568
Ensembl chr14:28,301,294...28,393,568
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
[Fenofibrate co-treated with Zinc] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased activity of TNF protein] |
CTD |
PMID:15226458 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
|
G |
GJA1 |
gap junction protein alpha 1 |
affects expression |
EXP |
Flutamide affects the expression of GJA1 mRNA |
CTD |
PMID:20961722 |
|
NCBI chr 1:40,988,818...41,002,129
Ensembl chr 1:40,988,528...41,002,156
|
|
|
G |
CAT |
catalase |
multiple interactions |
EXP |
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] promotes the reaction [bisphenol A results in decreased expression of CAT protein]; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT mRNA; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT protein |
CTD |
PMID:29129240 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
CBS |
cystathionine beta-synthase |
multiple interactions increases activity |
EXP |
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of CBS protein Folic Acid deficiency results in increased activity of CBS protein |
CTD |
PMID:16792574 |
|
NCBI chr13:206,205,942...206,231,363
Ensembl chr13:206,205,946...206,230,248
|
|
G |
CSF2 |
colony stimulating factor 2 |
multiple interactions |
EXP |
[Folic Acid co-treated with Glycine] results in decreased expression of CSF2 mRNA |
CTD |
PMID:14662146 |
|
NCBI chr 2:134,354,724...134,357,155
Ensembl chr 2:134,354,724...134,357,155
|
|
G |
CTH |
cystathionine gamma-lyase |
multiple interactions |
EXP |
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of CTH protein |
CTD |
PMID:16792574 |
|
NCBI chr 6:142,454,922...142,486,352
Ensembl chr 6:142,454,914...142,486,367
|
|
G |
DNMT1 |
DNA methyltransferase 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT1 mRNA |
CTD |
PMID:28445388 |
|
NCBI chr 2:68,981,564...69,040,364
Ensembl chr 2:68,981,566...69,029,844
|
|
G |
DNMT3A |
DNA methyltransferase 3 alpha |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of DNMT3A mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT3A mRNA |
CTD |
PMID:28445388 |
|
NCBI chr 3:113,501,972...113,609,148
Ensembl chr 3:113,528,926...113,603,087
|
|
G |
GCLC |
glutamate-cysteine ligase catalytic subunit |
multiple interactions |
EXP |
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of GCLC protein; [Ethanol co-treated with Folic Acid deficiency] results in increased expression of GCLC mRNA |
CTD |
PMID:16792574 |
|
NCBI chr 7:27,209,565...27,253,535
Ensembl chr 7:27,209,565...27,253,530
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of GPX1 mRNA; [bisphenol A co-treated with [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12]] results in increased expression of GPX1 mRNA |
CTD |
PMID:29129240 |
|
NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
|
|
G |
GSR |
glutathione-disulfide reductase |
multiple interactions increases activity increases expression |
EXP |
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of GSR protein; [Ethanol co-treated with Folic Acid deficiency] results in increased expression of GSR mRNA Folic Acid deficiency results in increased activity of GSR protein Folic Acid deficiency results in increased expression of GSR mRNA |
CTD |
PMID:16792574 |
|
NCBI chr15:54,382,564...54,433,989
Ensembl chr15:54,382,567...54,433,984
|
|
G |
GSS |
glutathione synthetase |
multiple interactions |
EXP |
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of GSS protein; [Ethanol co-treated with Folic Acid deficiency] results in increased expression of GSS mRNA |
CTD |
PMID:16792574 |
|
NCBI chr17:38,316,199...38,342,253
Ensembl chr17:38,312,720...38,342,298
|
|
G |
GYS1 |
glycogen synthase 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with bisphenol A] results in increased methylation of GYS1 promoter; [Betaine co-treated with Choline co-treated with Folic Acid] results in decreased expression of GYS1 mRNA; [Betaine co-treated with Choline co-treated with Folic Acid] results in increased methylation of GYS1 promoter |
CTD |
PMID:29065941 |
|
NCBI chr 6:54,234,600...54,250,211
Ensembl chr 6:54,233,050...54,250,261
|
|
G |
LDHA |
lactate dehydrogenase A |
multiple interactions |
EXP |
[bisphenol A co-treated with Choline co-treated with Folic Acid co-treated with Betaine] results in decreased methylation of LDHA promoter |
CTD |
PMID:29065941 |
|
NCBI chr 2:40,814,163...40,827,284
Ensembl chr 2:40,814,169...40,826,715
|
|
G |
LOC106504562 |
glutathione S-transferase alpha M14 |
increases expression multiple interactions |
EXP |
Folic Acid deficiency results in increased expression of GSTA1 mRNA [Ethanol co-treated with Folic Acid deficiency] results in increased expression of GSTA1 mRNA |
CTD |
PMID:16792574 |
|
NCBI chr 7:46,553,813...46,567,596
|
|
G |
MTHFR |
methylenetetrahydrofolate reductase |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of MTHFR mRNA |
CTD |
PMID:28445388 |
|
NCBI chr 6:71,863,637...71,882,118
Ensembl chr 6:71,863,637...71,881,820
|
|
G |
PTGS1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
EXP |
[Folic Acid co-treated with Glycine] results in decreased expression of PTGS1 |
CTD |
PMID:14662146 |
|
NCBI chr 1:262,456,106...262,482,159
Ensembl chr 1:262,456,155...262,483,035
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
[Folic Acid co-treated with Glycine] results in increased expression of PTGS2 |
CTD |
PMID:14662146 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
G |
SI |
sucrase-isomaltase |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SI mRNA |
CTD |
PMID:28445388 |
|
NCBI chr13:104,296,281...104,379,558
Ensembl chr13:104,296,283...104,379,478
|
|
G |
SLC15A1 |
solute carrier family 15 member 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of SLC15A1 mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased methylation of SLC15A1 promoter]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC15A1 mRNA |
CTD |
PMID:28445388 |
|
NCBI chr11:67,652,808...67,690,457
Ensembl chr11:67,652,193...67,710,933
|
|
G |
SLC5A1 |
solute carrier family 5 member 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with bisphenol A] results in increased expression of SLC5A1 mRNA; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC5A1 mRNA |
CTD |
PMID:28445388 |
|
NCBI chr14:48,566,400...48,704,145
Ensembl chr14:48,628,224...48,705,841
|
|
G |
SOD1 |
superoxide dismutase 1 |
decreases activity multiple interactions |
EXP |
Folic Acid deficiency results in decreased activity of SOD1 protein [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of SOD1 mRNA; [Ethanol co-treated with Folic Acid deficiency] results in decreased activity of SOD1 protein |
CTD |
PMID:16792574 PMID:29129240 |
|
NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
|
|
G |
SOD2 |
superoxide dismutase 2 |
multiple interactions increases activity |
EXP |
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of SOD2 protein Folic Acid deficiency results in increased activity of SOD2 protein; Folic Acid results in increased activity of SOD2 protein |
CTD |
PMID:16792574 PMID:22889112 |
|
NCBI chr 1:7,679,352...7,689,564
Ensembl chr 1:7,679,352...7,689,560
|
|
|
G |
ATP4A |
ATPase H+/K+ transporting subunit alpha |
decreases expression |
EXP |
formic acid results in decreased expression of ATP4A mRNA |
CTD |
PMID:16614409 |
|
NCBI chr 6:44,984,014...45,057,796
Ensembl chr 6:44,984,233...44,997,552
|
|
|
G |
AGER |
advanced glycosylation end-product specific receptor |
increases expression |
EXP |
fumonisin B1 results in increased expression of AGER mRNA |
CTD |
PMID:32198028 |
|
NCBI chr 7:24,218,116...24,221,162
Ensembl chr 7:24,218,120...24,221,162
|
|
G |
APAF1 |
apoptotic peptidase activating factor 1 |
multiple interactions increases expression |
EXP |
fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of APAF1 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of APAF1 protein] fumonisin B1 results in increased expression of APAF1 mRNA; fumonisin B1 results in increased expression of APAF1 protein |
CTD |
PMID:36397609 |
|
NCBI chr 5:85,166,616...85,258,751
Ensembl chr 5:85,166,628...85,258,364
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP |
[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of BAX mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of BAX protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of BAX mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA] fumonisin B1 results in increased expression of BAX mRNA; fumonisin B1 results in increased expression of BAX protein |
CTD |
PMID:33905761 PMID:36397609 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression multiple interactions |
EXP |
fumonisin B1 results in decreased expression of BCL2 mRNA; fumonisin B1 results in decreased expression of BCL2 protein [Acetylcysteine co-treated with fumonisin B1 co-treated with deoxynivalenol] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with fumonisin B1] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of BCL2 protein; [fumonisin B1 co-treated with deoxynivalenol] results in decreased expression of BCL2 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein; [fumonisin B1 co-treated with Zearalenone co-treated with deoxynivalenol] results in decreased expression of BCL2 protein; [fumonisin B1 co-treated with Zearalenone] results in decreased expression of BCL2 mRNA; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in decreased expression of BCL2 mRNA]]; fumonisin B1 inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]; fumonisin B1 inhibits the reaction [Zearalenone inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 mRNA]]; fumonisin B1 promotes the reaction [ochratoxin A results in decreased expression of BCL2 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in decreased expression of BCL2 protein]; fumonisin B1 promotes the reaction [Zearalenone results in decreased expression of BCL2 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in decreased expression of BCL2 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; Zearalenone inhibits the reaction [fumonisin B1 inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]]; Zearalenone inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in decreased expression of BCL2 mRNA]] |
CTD |
PMID:29109043 PMID:33905761 PMID:36397609 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
CASP1 |
caspase 1, apoptosis-related cysteine peptidase |
multiple interactions |
EXP |
N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP1 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP1 protein] |
CTD |
PMID:36309173 |
|
NCBI chr 9:35,188,066...35,199,364
Ensembl chr 9:35,186,420...35,200,328
|
|
G |
CASP10 |
caspase 10 |
multiple interactions increases expression |
EXP |
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of CASP10 mRNA] |
CTD |
PMID:32198028 |
|
NCBI chr15:104,858,082...104,895,941
Ensembl chr15:104,858,100...104,894,933
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases expression |
EXP |
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of CASP3 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of CASP3 protein]; [fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA; [fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form; [fumonisin B1 co-treated with Zearalenone] promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]; [fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA; [fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 protein]; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA]]; deoxynivalenol promotes the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA]; fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CASP3 mRNA]]; fumonisin B1 promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 protein modified form]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 protein]; fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 mRNA]]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 protein modified form]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein]; Zearalenone promotes the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA] fumonisin B1 results in increased expression of CASP3 mRNA; fumonisin B1 results in increased expression of CASP3 protein; fumonisin B1 results in increased expression of CASP3 protein modified form |
CTD |
PMID:29109043 PMID:32198028 PMID:33905761 PMID:36397609 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CASP8 |
caspase 8 |
multiple interactions increases expression |
EXP |
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of CASP8 mRNA] |
CTD |
PMID:32198028 |
|
NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468
|
|
G |
CASP9 |
caspase 9 |
multiple interactions increases expression |
EXP |
[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 protein modified form]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 protein modified form]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein] fumonisin B1 results in increased expression of CASP9 mRNA; fumonisin B1 results in increased expression of CASP9 protein; fumonisin B1 results in increased expression of CASP9 protein modified form |
CTD |
PMID:33905761 PMID:36397609 |
|
NCBI chr 6:74,707,597...74,730,033
Ensembl chr 6:74,706,516...74,730,007
|
|
G |
CCL2 |
chemokine (C-C motif) ligand 2 |
multiple interactions decreases expression increases expression |
EXP |
[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA] fumonisin B1 results in decreased expression of CCL2 mRNA fumonisin B1 metabolite results in increased expression of CCL2 mRNA; fumonisin B1 results in increased expression of CCL2 mRNA |
CTD |
PMID:23688591 PMID:30708112 |
|
NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026
|
|
G |
CCL20 |
C-C motif chemokine ligand 20 |
increases expression multiple interactions |
EXP |
fumonisin B1 results in increased expression of CCL20 mRNA fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA] |
CTD |
PMID:30708112 |
|
NCBI chr15:129,172,743...129,176,069
|
|
G |
CHUK |
component of inhibitor of nuclear factor kappa B kinase complex |
increases expression |
EXP |
fumonisin B1 results in increased expression of CHUK mRNA |
CTD |
PMID:32198028 |
|
NCBI chr14:111,316,178...111,351,669
Ensembl chr14:111,315,141...111,351,868
|
|
G |
CLDN1 |
claudin 1 |
decreases expression |
EXP |
fumonisin B1 results in decreased expression of CLDN1 mRNA; fumonisin B1 results in decreased expression of CLDN1 protein |
CTD |
PMID:31557363 |
|
NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions increases expression |
EXP |
[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CXCL8 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CXCL8 mRNA] fumonisin B1 results in increased expression of CXCL8 mRNA |
CTD |
PMID:23688591 PMID:30708112 |
|
NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861
|
|
G |
CYCS |
cytochrome c, somatic |
multiple interactions |
EXP |
[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [[Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA]]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA]]; deoxynivalenol promotes the reaction [[Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA]; fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CYCS mRNA]; Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA] |
CTD |
PMID:29109043 PMID:36397609 |
|
NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
|
|
G |
GSDMD |
gasdermin D |
multiple interactions |
EXP |
belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of GSDMD mRNA]; belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of GSDMD protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of GSDMD mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of GSDMD protein] |
CTD |
PMID:36309173 |
|
NCBI chr 4:995,753...1,001,964
Ensembl chr 4:995,763...1,000,271
|
|
G |
GSR |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]]; fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]; fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]; Zearalenone promotes the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]] |
CTD |
PMID:29109043 |
|
NCBI chr15:54,382,564...54,433,989
Ensembl chr15:54,382,567...54,433,984
|
|
G |
HAVCR1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
EXP |
[fumonisin B1 co-treated with ochratoxin A] results in increased expression of HAVCR1 mRNA |
CTD |
PMID:33905761 |
|
NCBI chr16:66,162,318...66,208,868
|
|
G |
IFNG |
interferon gamma |
decreases expression |
EXP |
fumonisin B1 metabolite results in decreased expression of IFNG protein |
CTD |
PMID:30708112 |
|
NCBI chr 5:32,477,906...32,482,670
Ensembl chr 5:32,477,906...32,482,670
|
|
G |
IL17A |
interleukin 17A |
multiple interactions |
EXP |
fumonisin B1 inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of IL17A protein]; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of IL17A protein] |
CTD |
PMID:30708112 |
|
NCBI chr 7:46,013,584...46,017,161
Ensembl chr 7:46,013,584...46,017,153
|
|
G |
IL18 |
interleukin 18 |
multiple interactions |
EXP |
belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL18 mRNA]; belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL18 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL18 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL18 protein] |
CTD |
PMID:36309173 |
|
NCBI chr 9:39,839,959...39,861,258
Ensembl chr 9:39,834,973...39,861,219
|
|
G |
IL1A |
interleukin 1 alpha |
multiple interactions increases expression decreases expression |
EXP |
[deoxynivalenol co-treated with fumonisin B1] results in decreased expression of IL1A mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA fumonisin B1 results in increased expression of IL1A mRNA fumonisin B1 results in decreased expression of IL1A mRNA |
CTD |
PMID:23688591 |
|
NCBI chr 3:43,718,320...43,731,668
Ensembl chr 3:43,718,368...43,731,119
|
|
G |
IL6 |
interleukin 6 |
multiple interactions decreases expression increases expression |
EXP |
[deoxynivalenol co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [nivalenol co-treated with fumonisin B1] results in decreased expression of IL6 mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA fumonisin B1 results in decreased expression of IL6 mRNA fumonisin B1 results in increased expression of IL6 mRNA |
CTD |
PMID:23688591 PMID:30708112 |
|
NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
|
|
G |
LCN2 |
lipocalin 2 |
multiple interactions |
EXP |
[fumonisin B1 co-treated with ochratoxin A] results in increased expression of LCN2 mRNA |
CTD |
PMID:33905761 |
|
NCBI chr 1:268,609,975...268,614,651
Ensembl chr 1:268,609,887...268,614,644
|
|
G |
LOC110258578 |
interleukin-1 beta-like |
increases expression multiple interactions |
EXP |
fumonisin B1 results in increased expression of IL1B mRNA [deoxynivalenol co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL1B mRNA]; belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL1B mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL1B protein] |
CTD |
PMID:23688591 PMID:36309173 |
|
|
|
G |
MAP3K14 |
mitogen-activated protein kinase kinase kinase 14 |
increases expression |
EXP |
fumonisin B1 results in increased expression of MAP3K14 mRNA |
CTD |
PMID:32198028 |
|
NCBI chr12:18,142,899...18,182,931
Ensembl chr12:18,142,952...18,182,928
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
increases phosphorylation |
EXP |
fumonisin B1 results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:31557363 |
|
NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513
|
|
G |
MAPK10 |
mitogen-activated protein kinase 10 |
increases expression multiple interactions |
EXP |
fumonisin B1 results in increased expression of MAPK10 mRNA 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of MAPK10 mRNA] |
CTD |
PMID:32198028 |
|
NCBI chr 8:132,445,818...132,751,575
Ensembl chr 8:132,298,299...132,776,820
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
increases phosphorylation |
EXP |
fumonisin B1 results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:31557363 |
|
NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
increases expression multiple interactions |
EXP |
fumonisin B1 results in increased expression of MAPK8 mRNA; fumonisin B1 results in increased expression of MAPK8 protein 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of MAPK8 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of MAPK8 protein] |
CTD |
PMID:32198028 |
|
NCBI chr14:88,988,914...89,108,875
Ensembl chr14:88,988,949...89,108,874
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
increases expression multiple interactions |
EXP |
fumonisin B1 results in increased expression of MAPK9 mRNA 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of MAPK9 mRNA] |
CTD |
PMID:32198028 |
|
NCBI chr 2:78,338,466...78,399,108
Ensembl chr 2:78,338,376...78,399,100
|
|
G |
MUC1 |
mucin 1, cell surface associated |
decreases expression |
EXP |
fumonisin B1 results in decreased expression of MUC1 mRNA |
CTD |
PMID:31557363 |
|
NCBI chr 4:94,626,317...94,631,194
|
|
G |
MUC2 |
mucin 2, oligomeric mucus/gel-forming |
increases expression |
EXP |
fumonisin B1 results in increased expression of MUC2 mRNA |
CTD |
PMID:31557363 |
|
NCBI chr 2:689,363...719,542
Ensembl chr 2:689,364...710,330
|
|
G |
NFKB1 |
nuclear factor kappa B subunit 1 |
increases expression multiple interactions |
EXP |
fumonisin B1 results in increased expression of NFKB1 mRNA; fumonisin B1 results in increased expression of NFKB1 protein 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of NFKB1 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of NFKB1 protein] |
CTD |
PMID:32198028 |
|
NCBI chr 8:118,391,010...118,478,927
Ensembl chr 8:118,390,638...118,506,691
|
|
G |
NTN1 |
netrin 1 |
multiple interactions |
EXP |
fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of NTN1 mRNA] |
CTD |
PMID:33905761 |
|
NCBI chr12:54,089,444...54,292,191
Ensembl chr12:54,089,472...54,292,193
|
|
G |
OCLN |
occludin |
decreases expression |
EXP |
fumonisin B1 results in decreased expression of OCLN mRNA; fumonisin B1 results in decreased expression of OCLN protein |
CTD |
PMID:31557363 |
|
NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033
|
|
G |
SLC15A1 |
solute carrier family 15 member 1 |
increases expression |
EXP |
fumonisin B1 results in increased expression of SLC15A1 mRNA |
CTD |
PMID:33443779 |
|
NCBI chr11:67,652,808...67,690,457
Ensembl chr11:67,652,193...67,710,933
|
|
G |
SLC1A1 |
solute carrier family 1 member 1 |
decreases expression |
EXP |
fumonisin B1 results in decreased expression of SLC1A1 mRNA |
CTD |
PMID:33443779 |
|
NCBI chr 1:217,366,493...217,441,643
Ensembl chr 1:217,366,499...217,441,674
|
|
G |
SLC27A4 |
solute carrier family 27 member 4 |
decreases expression |
EXP |
fumonisin B1 results in decreased expression of SLC27A4 mRNA |
CTD |
PMID:33443779 |
|
NCBI chr 1:268,773,792...268,788,208
Ensembl chr 1:268,773,806...268,788,731
|
|
G |
SLC2A2 |
solute carrier family 2 member 2 |
decreases expression |
EXP |
fumonisin B1 results in decreased expression of SLC2A2 mRNA |
CTD |
PMID:33443779 |
|
NCBI chr13:109,592,595...109,614,105
Ensembl chr13:109,587,258...109,638,510
|
|
G |
SLC7A1 |
solute carrier family 7 member 1 |
decreases expression |
EXP |
fumonisin B1 results in decreased expression of SLC7A1 mRNA |
CTD |
PMID:33443779 |
|
NCBI chr11:6,538,053...6,604,654
Ensembl chr11:6,538,045...6,604,658
|
|
G |
SLC7A7 |
solute carrier family 7 member 7 |
decreases expression |
EXP |
fumonisin B1 results in decreased expression of SLC7A7 mRNA |
CTD |
PMID:33443779 |
|
NCBI chr 7:76,195,774...76,235,406
Ensembl chr 7:76,198,256...76,235,402
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
increases expression multiple interactions |
EXP |
fumonisin B1 results in increased expression of SPP1 mRNA fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of SPP1 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of SPP1 mRNA] |
CTD |
PMID:33905761 |
|
NCBI chr 8:131,077,786...131,085,334
Ensembl chr 8:131,077,786...131,085,340
|
|
G |
TJP1 |
tight junction protein 1 |
decreases expression |
EXP |
fumonisin B1 results in decreased expression of TJP1 mRNA; fumonisin B1 results in decreased expression of TJP1 protein |
CTD |
PMID:31557363 |
|
NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions increases expression |
EXP |
[deoxynivalenol co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Lipopolysaccharides co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Lipopolysaccharides co-treated with fumonisin B1] results in increased expression of TNF protein; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of TNF mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA fumonisin B1 results in increased expression of TNF mRNA; fumonisin B1 results in increased expression of TNF protein |
CTD |
PMID:23688591 PMID:30708112 PMID:32198028 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
G |
TP53 |
tumor protein p53 |
increases expression multiple interactions |
EXP |
fumonisin B1 results in increased expression of TP53 mRNA [deoxynivalenol co-treated with fumonisin B1] results in increased expression of TP53 mRNA; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in increased expression of TP53 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 results in increased expression of TP53 mRNA]]; fumonisin B1 inhibits the reaction [deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA]]; fumonisin B1 promotes the reaction [Zearalenone results in increased expression of TP53 mRNA]; Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of TP53 mRNA]; Zearalenone promotes the reaction [fumonisin B1 results in increased expression of TP53 mRNA] |
CTD |
PMID:29109043 |
|
NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818
|
|
G |
TRADD |
TNFRSF1A associated via death domain |
increases expression |
EXP |
fumonisin B1 results in increased expression of TRADD mRNA |
CTD |
PMID:32198028 |
|
NCBI chr 6:27,797,594...27,804,654
Ensembl chr 6:27,797,607...27,804,423
|
|
G |
TRAF2 |
TNF receptor associated factor 2 |
increases expression |
EXP |
fumonisin B1 results in increased expression of TRAF2 mRNA |
CTD |
PMID:32198028 |
|
|
|
|
G |
CACNA2D1 |
calcium voltage-gated channel auxiliary subunit alpha2delta 1 |
affects binding |
EXP |
Gabapentin binds to CACNA2D1 protein |
CTD |
PMID:11687876 |
|
NCBI chr 9:97,781,057...98,265,925
Ensembl chr 9:97,781,090...98,266,969
|
|
|
G |
AOC1 |
amine oxidase copper containing 1 |
multiple interactions |
EXP |
Glutathione inhibits the reaction [Paraquat results in increased expression of AOC1 protein] |
CTD |
PMID:36615853 |
|
NCBI chr18:6,309,583...6,321,016
Ensembl chr18:6,309,594...6,320,974
|
|
G |
CYP2B6B |
cytochrome P450 family 2 subfamily B member 6B |
multiple interactions |
EXP |
[Glutathione co-treated with Paraquat] results in decreased expression of CYP2B6B mRNA |
CTD |
PMID:36615853 |
|
NCBI chr 6:49,158,175...49,173,872
Ensembl chr 6:49,110,812...49,178,334
|
|
G |
CYP3A39 |
cytochrome P450 3A39 |
multiple interactions |
EXP |
Glutathione inhibits the reaction [Paraquat results in increased expression of CYP3A39 mRNA] |
CTD |
PMID:36615853 |
|
|
|
G |
DNAJC7 |
DnaJ heat shock protein family (Hsp40) member C7 |
multiple interactions |
EXP |
[Glutathione co-treated with Paraquat] results in increased expression of DNAJC7 mRNA |
CTD |
PMID:36615853 |
|
NCBI chr12:20,725,937...20,756,295
Ensembl chr12:20,725,975...20,759,000
|
|
G |
FABP2 |
fatty acid binding protein 2 |
multiple interactions |
EXP |
Glutathione inhibits the reaction [Paraquat results in increased activity of FABP2 protein] |
CTD |
PMID:36615853 |
|
NCBI chr 8:104,464,342...104,468,059
Ensembl chr 8:104,464,342...104,470,480
|
|
G |
GCLM |
glutamate-cysteine ligase modifier subunit |
multiple interactions |
EXP |
[Glutathione co-treated with Paraquat] results in increased expression of GCLM mRNA |
CTD |
PMID:36615853 |
|
NCBI chr 4:123,371,198...123,390,130
Ensembl chr 4:123,371,193...123,390,131
|
|
G |
GPX4 |
glutathione peroxidase 4 |
multiple interactions |
EXP |
[Glutathione co-treated with Paraquat] results in increased expression of GPX4 mRNA |
CTD |
PMID:36615853 |
|
NCBI chr 2:77,321,568...77,323,931
Ensembl chr 2:77,320,464...77,323,931
|
|
G |
HSP90AA1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
EXP |
[Glutathione co-treated with Paraquat] results in decreased expression of HSP90AA1 mRNA |
CTD |
PMID:36615853 |
|
|
|
G |
IDH2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions |
EXP |
Glutathione inhibits the reaction [Cadmium Chloride results in decreased activity of IDH2 protein]; Glutathione inhibits the reaction [Cadmium results in decreased activity of IDH2 protein] |
CTD |
PMID:16785314 |
|
NCBI chr 7:55,654,298...55,675,571
Ensembl chr 7:55,651,609...55,675,554
|
|
G |
IFNG |
interferon gamma |
multiple interactions |
EXP |
Glutathione inhibits the reaction [Paraquat results in increased expression of IFNG mRNA] |
CTD |
PMID:36615853 |
|
NCBI chr 5:32,477,906...32,482,670
Ensembl chr 5:32,477,906...32,482,670
|
|
G |
IL10 |
interleukin 10 |
multiple interactions |
EXP |
[Glutathione co-treated with Paraquat] results in increased expression of IL10 mRNA |
CTD |
PMID:36615853 |
|
NCBI chr 9:67,400,727...67,405,941
Ensembl chr 9:67,400,728...67,405,378
|
|
G |
LOC100739508 |
glutathione S-transferase P-like |
multiple interactions |
EXP |
GSTP1 protein affects the metabolism of [monobromobimane co-treated with Glutathione] |
CTD |
PMID:14573868 |
|
NCBI chr 2:5,005,498...5,009,247
|
|
G |
LOC106504562 |
glutathione S-transferase alpha M14 |
multiple interactions |
EXP |
[Glutathione co-treated with Paraquat] results in increased expression of GSTA2 mRNA; Glutathione inhibits the reaction [Paraquat results in decreased expression of GSTA1 mRNA] |
CTD |
PMID:36615853 |
|
NCBI chr 7:46,553,813...46,567,596
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
multiple interactions |
EXP |
Glutathione inhibits the reaction [Paraquat results in increased expression of NR1I3 mRNA] |
CTD |
PMID:36615853 |
|
NCBI chr 4:89,226,314...89,231,781
Ensembl chr 4:89,226,690...89,236,431
|
|
G |
OCLN |
occludin |
multiple interactions |
EXP |
Glutathione inhibits the reaction [Paraquat results in decreased expression of OCLN protein] |
CTD |
PMID:36615853 |
|
NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033
|
|
G |
SOD2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
[Glutathione co-treated with Paraquat] affects the expression of SOD2 mRNA |
CTD |
PMID:36615853 |
|
NCBI chr 1:7,679,352...7,689,564
Ensembl chr 1:7,679,352...7,689,560
|
|
G |
TJP1 |
tight junction protein 1 |
multiple interactions |
EXP |
Glutathione inhibits the reaction [Paraquat results in decreased expression of TJP1 protein] |
CTD |
PMID:36615853 |
|
NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836
|
|
|
G |
EDN1 |
endothelin 1 |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Carvedilol results in decreased expression of EDN1 protein] |
CTD |
PMID:18840580 |
|
NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348
|
|
|
G |
CSF2 |
colony stimulating factor 2 |
multiple interactions |
EXP |
[Folic Acid co-treated with Glycine] results in decreased expression of CSF2 mRNA |
CTD |
PMID:14662146 |
|
NCBI chr 2:134,354,724...134,357,155
Ensembl chr 2:134,354,724...134,357,155
|
|
G |
PTGS1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
EXP |
[Folic Acid co-treated with Glycine] results in decreased expression of PTGS1 |
CTD |
PMID:14662146 |
|
NCBI chr 1:262,456,106...262,482,159
Ensembl chr 1:262,456,155...262,483,035
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
[Folic Acid co-treated with Glycine] results in increased expression of PTGS2 |
CTD |
PMID:14662146 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
|
G |
ATF4 |
activating transcription factor 4 |
multiple interactions |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of ATF4 mRNA]; Betaine inhibits the reaction [glyphosate results in increased expression of ATF4 protein] |
CTD |
PMID:36584959 |
|
NCBI chr 5:8,742,964...8,745,752
Ensembl chr 5:8,742,967...8,745,368
|
|
G |
ATF6 |
activating transcription factor 6 |
multiple interactions |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of ATF6 mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr 4:88,591,279...88,806,156
Ensembl chr 4:88,591,288...88,805,304
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
[Betaine co-treated with glyphosate] results in increased expression of BAX mRNA |
CTD |
PMID:36584959 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of CASP3 mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of CASP9 mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr 6:74,707,597...74,730,033
Ensembl chr 6:74,706,516...74,730,007
|
|
G |
CAT |
catalase |
multiple interactions |
EXP |
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] promotes the reaction [bisphenol A results in decreased expression of CAT protein]; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT mRNA; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT protein; Betaine inhibits the reaction [glyphosate results in increased expression of CAT mRNA] |
CTD |
PMID:29129240 PMID:36584959 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
CLDN1 |
claudin 1 |
multiple interactions |
EXP |
Betaine inhibits the reaction [glyphosate results in decreased expression of CLDN1 mRNA]; Betaine inhibits the reaction [glyphosate results in decreased expression of CLDN1 protein] |
CTD |
PMID:36584959 |
|
NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
multiple interactions |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of DDIT3 mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829
|
|
G |
DNMT1 |
DNA methyltransferase 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT1 mRNA |
CTD |
PMID:28445388 |
|
NCBI chr 2:68,981,564...69,040,364
Ensembl chr 2:68,981,566...69,029,844
|
|
G |
DNMT3A |
DNA methyltransferase 3 alpha |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of DNMT3A mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT3A mRNA |
CTD |
PMID:28445388 |
|
NCBI chr 3:113,501,972...113,609,148
Ensembl chr 3:113,528,926...113,603,087
|
|
G |
EIF2AK3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of EIF2AK3 mRNA]; Betaine inhibits the reaction [glyphosate results in increased expression of EIF2AK3 protein] |
CTD |
PMID:36584959 |
|
NCBI chr 3:57,423,894...57,506,247
Ensembl chr 3:57,423,943...57,506,245
|
|
G |
EIF2S1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of EIF2S1 mRNA]; Betaine inhibits the reaction [glyphosate results in increased expression of EIF2S1 protein] |
CTD |
PMID:36584959 |
|
NCBI chr 7:91,085,025...91,109,835
Ensembl chr 7:91,085,335...91,109,827
|
|
G |
ERN1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of ERN1 mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr12:14,881,913...14,963,290
Ensembl chr12:14,881,923...14,963,284
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of GPX1 mRNA; [bisphenol A co-treated with [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12]] results in increased expression of GPX1 mRNA |
CTD |
PMID:29129240 |
|
NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
|
|
G |
GPX2 |
glutathione peroxidase 2 |
multiple interactions |
EXP |
[Betaine co-treated with glyphosate] results in increased expression of GPX2 mRNA |
CTD |
PMID:36584959 |
|
NCBI chr 7:89,007,636...89,011,620
Ensembl chr 7:89,007,375...89,011,620
|
|
G |
GYS1 |
glycogen synthase 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with bisphenol A] results in increased methylation of GYS1 promoter; [Betaine co-treated with Choline co-treated with Folic Acid] results in decreased expression of GYS1 mRNA; [Betaine co-treated with Choline co-treated with Folic Acid] results in increased methylation of GYS1 promoter |
CTD |
PMID:29065941 |
|
NCBI chr 6:54,234,600...54,250,211
Ensembl chr 6:54,233,050...54,250,261
|
|
G |
HSP90B1 |
heat shock protein 90 beta family member 1 |
multiple interactions |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of HSP90B1 mRNA]; Betaine inhibits the reaction [glyphosate results in increased expression of HSP90B1 protein] |
CTD |
PMID:36584959 |
|
NCBI chr 5:80,511,513...80,531,016
Ensembl chr 5:80,511,506...80,530,991
|
|
G |
LDHA |
lactate dehydrogenase A |
multiple interactions |
EXP |
[bisphenol A co-treated with Choline co-treated with Folic Acid co-treated with Betaine] results in decreased methylation of LDHA promoter |
CTD |
PMID:29065941 |
|
NCBI chr 2:40,814,163...40,827,284
Ensembl chr 2:40,814,169...40,826,715
|
|
G |
MFN1 |
mitofusin 1 |
multiple interactions |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of MFN1 mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr13:117,404,637...117,441,750
Ensembl chr13:117,404,699...117,442,481
|
|
G |
MTHFR |
methylenetetrahydrofolate reductase |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of MTHFR mRNA |
CTD |
PMID:28445388 |
|
NCBI chr 6:71,863,637...71,882,118
Ensembl chr 6:71,863,637...71,881,820
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of NFE2L2 mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of NQO1 mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr 6:17,292,962...17,302,593
Ensembl chr 6:17,292,770...17,302,590
|
|
G |
PCNA |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of PCNA mRNA]; Betaine inhibits the reaction [glyphosate results in increased expression of PCNA protein] |
CTD |
PMID:36584959 |
|
NCBI chr17:14,137,746...14,142,584
Ensembl chr17:14,136,886...14,142,744
|
|
G |
SDHA |
succinate dehydrogenase complex flavoprotein subunit A |
multiple interactions |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of SDHA mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr16:79,838,442...79,862,956
Ensembl chr16:79,834,044...79,862,524
|
|
G |
SI |
sucrase-isomaltase |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SI mRNA |
CTD |
PMID:28445388 |
|
NCBI chr13:104,296,281...104,379,558
Ensembl chr13:104,296,283...104,379,478
|
|
G |
SLC15A1 |
solute carrier family 15 member 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of SLC15A1 mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased methylation of SLC15A1 promoter]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC15A1 mRNA |
CTD |
PMID:28445388 |
|
NCBI chr11:67,652,808...67,690,457
Ensembl chr11:67,652,193...67,710,933
|
|
G |
SLC5A1 |
solute carrier family 5 member 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with bisphenol A] results in increased expression of SLC5A1 mRNA; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC5A1 mRNA |
CTD |
PMID:28445388 |
|
NCBI chr14:48,566,400...48,704,145
Ensembl chr14:48,628,224...48,705,841
|
|
G |
SOD1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of SOD1 mRNA |
CTD |
PMID:29129240 |
|
NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
|
|
G |
SOD2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of SOD2 mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr 1:7,679,352...7,689,564
Ensembl chr 1:7,679,352...7,689,560
|
|
G |
UQCRB |
ubiquinol-cytochrome c reductase binding protein |
multiple interactions |
EXP |
[Betaine co-treated with glyphosate] results in decreased expression of UQCRB mRNA |
CTD |
PMID:36584959 |
|
NCBI chr 4:40,403,272...40,409,080
Ensembl chr 4:40,403,109...40,409,057
|
|
G |
XBP1 |
X-box binding protein 1 |
multiple interactions |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of XBP1 mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr14:46,011,239...46,016,526
Ensembl chr14:46,008,377...46,016,526
|
|
|
G |
ATF4 |
activating transcription factor 4 |
increases expression multiple interactions |
EXP |
glyphosate results in increased expression of ATF4 mRNA; glyphosate results in increased expression of ATF4 protein Betaine inhibits the reaction [glyphosate results in increased expression of ATF4 mRNA]; Betaine inhibits the reaction [glyphosate results in increased expression of ATF4 protein] |
CTD |
PMID:36584959 |
|
NCBI chr 5:8,742,964...8,745,752
Ensembl chr 5:8,742,967...8,745,368
|
|
G |
ATF6 |
activating transcription factor 6 |
increases expression multiple interactions |
EXP |
glyphosate results in increased expression of ATF6 mRNA Betaine inhibits the reaction [glyphosate results in increased expression of ATF6 mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr 4:88,591,279...88,806,156
Ensembl chr 4:88,591,288...88,805,304
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP |
[Betaine co-treated with glyphosate] results in increased expression of BAX mRNA glyphosate results in increased expression of BAX mRNA |
CTD |
PMID:36584959 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
CASP3 |
caspase 3 |
increases expression multiple interactions |
EXP |
glyphosate results in increased expression of CASP3 mRNA Betaine inhibits the reaction [glyphosate results in increased expression of CASP3 mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CASP9 |
caspase 9 |
increases expression multiple interactions |
EXP |
glyphosate results in increased expression of CASP9 mRNA Betaine inhibits the reaction [glyphosate results in increased expression of CASP9 mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr 6:74,707,597...74,730,033
Ensembl chr 6:74,706,516...74,730,007
|
|
G |
CAT |
catalase |
increases activity multiple interactions increases expression |
EXP |
glyphosate results in increased activity of CAT protein Betaine inhibits the reaction [glyphosate results in increased expression of CAT mRNA] |
CTD |
PMID:31677563 PMID:36584959 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
CLDN1 |
claudin 1 |
decreases expression multiple interactions |
EXP |
glyphosate results in decreased expression of CLDN1 mRNA; glyphosate results in decreased expression of CLDN1 protein Betaine inhibits the reaction [glyphosate results in decreased expression of CLDN1 mRNA]; Betaine inhibits the reaction [glyphosate results in decreased expression of CLDN1 protein] |
CTD |
PMID:31677563 PMID:36584959 |
|
NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
increases expression multiple interactions |
EXP |
glyphosate results in increased expression of CXCL8 mRNA pyrrolidine dithiocarbamic acid inhibits the reaction [glyphosate results in increased expression of CXCL8 mRNA] |
CTD |
PMID:35388968 |
|
NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
multiple interactions increases expression |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of DDIT3 mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829
|
|
G |
EIF2AK3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases expression multiple interactions |
EXP |
glyphosate results in increased expression of EIF2AK3 mRNA; glyphosate results in increased expression of EIF2AK3 protein Betaine inhibits the reaction [glyphosate results in increased expression of EIF2AK3 mRNA]; Betaine inhibits the reaction [glyphosate results in increased expression of EIF2AK3 protein] |
CTD |
PMID:36584959 |
|
NCBI chr 3:57,423,894...57,506,247
Ensembl chr 3:57,423,943...57,506,245
|
|
G |
EIF2S1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions increases expression |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of EIF2S1 mRNA]; Betaine inhibits the reaction [glyphosate results in increased expression of EIF2S1 protein] glyphosate results in increased expression of EIF2S1 mRNA; glyphosate results in increased expression of EIF2S1 protein |
CTD |
PMID:36584959 |
|
NCBI chr 7:91,085,025...91,109,835
Ensembl chr 7:91,085,335...91,109,827
|
|
G |
ERN1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions increases expression |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of ERN1 mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr12:14,881,913...14,963,290
Ensembl chr12:14,881,923...14,963,284
|
|
G |
GCLM |
glutamate-cysteine ligase modifier subunit |
decreases expression |
EXP |
glyphosate results in decreased expression of GCLM mRNA |
CTD |
PMID:31677563 PMID:35388968 |
|
NCBI chr 4:123,371,198...123,390,130
Ensembl chr 4:123,371,193...123,390,131
|
|
G |
GPX1 |
glutathione peroxidase 1 |
decreases expression decreases activity |
EXP |
glyphosate results in decreased expression of GPX1 mRNA glyphosate results in decreased activity of GPX1 protein |
CTD |
PMID:31677563 PMID:35388968 |
|
NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
|
|
G |
GPX2 |
glutathione peroxidase 2 |
multiple interactions |
EXP |
[Betaine co-treated with glyphosate] results in increased expression of GPX2 mRNA |
CTD |
PMID:36584959 |
|
NCBI chr 7:89,007,636...89,011,620
Ensembl chr 7:89,007,375...89,011,620
|
|
G |
GSTO1 |
glutathione S-transferase omega 1 |
increases expression |
EXP |
glyphosate results in increased expression of GSTO1 mRNA |
CTD |
PMID:36584959 |
|
NCBI chr14:115,206,434...115,216,624
Ensembl chr14:115,206,188...115,216,613
|
|
G |
HMOX1 |
heme oxygenase 1 |
decreases expression multiple interactions increases expression |
EXP |
glyphosate results in decreased expression of HMOX1 mRNA glyphosate results in increased expression of and affects the localization of HMOX1 protein glyphosate results in increased expression of HMOX1 mRNA |
CTD |
PMID:31677563 PMID:35388968 PMID:36584959 |
|
|
|
G |
HSP90B1 |
heat shock protein 90 beta family member 1 |
increases expression multiple interactions |
EXP |
glyphosate results in increased expression of HSP90B1 mRNA; glyphosate results in increased expression of HSP90B1 protein Betaine inhibits the reaction [glyphosate results in increased expression of HSP90B1 mRNA]; Betaine inhibits the reaction [glyphosate results in increased expression of HSP90B1 protein] |
CTD |
PMID:36584959 |
|
NCBI chr 5:80,511,513...80,531,016
Ensembl chr 5:80,511,506...80,530,991
|
|
G |
IL10 |
interleukin 10 |
increases expression |
EXP |
glyphosate results in increased expression of IL10 protein |
CTD |
PMID:36584959 |
|
NCBI chr 9:67,400,727...67,405,941
Ensembl chr 9:67,400,728...67,405,378
|
|
G |
IL6 |
interleukin 6 |
increases expression multiple interactions affects secretion |
EXP |
glyphosate results in increased expression of IL6 mRNA; glyphosate results in increased expression of IL6 protein pyrrolidine dithiocarbamic acid inhibits the reaction [glyphosate results in increased expression of IL6 mRNA] glyphosate affects the secretion of IL6 protein |
CTD |
PMID:31677563 PMID:35388968 PMID:36584959 |
|
NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
|
|
G |
KEAP1 |
kelch like ECH associated protein 1 |
decreases expression |
EXP |
glyphosate results in decreased expression of KEAP1 mRNA |
CTD |
PMID:35388968 |
|
NCBI chr 2:69,280,940...69,290,267
Ensembl chr 2:69,276,336...69,294,382
|
|
G |
LOC110258578 |
interleukin-1 beta-like |
multiple interactions increases expression increases secretion |
EXP |
pyrrolidine dithiocarbamic acid inhibits the reaction [glyphosate results in increased expression of IL1B mRNA] glyphosate results in increased expression of IL1B mRNA; glyphosate results in increased expression of IL1B protein glyphosate results in increased secretion of IL1B protein |
CTD |
PMID:35388968 PMID:36584959 |
|
|
|
G |
MFN1 |
mitofusin 1 |
multiple interactions increases expression |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of MFN1 mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr13:117,404,637...117,441,750
Ensembl chr13:117,404,699...117,442,481
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
increases expression multiple interactions |
EXP |
glyphosate results in increased expression of NFE2L2 mRNA; glyphosate results in increased expression of NFE2L2 protein Betaine inhibits the reaction [glyphosate results in increased expression of NFE2L2 mRNA]; glyphosate results in increased expression of and affects the localization of NFE2L2 protein |
CTD |
PMID:31677563 PMID:35388968 PMID:36584959 |
|
NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183
|
|
G |
NFKB1 |
nuclear factor kappa B subunit 1 |
increases expression |
EXP |
glyphosate results in increased expression of NFKB1 mRNA |
CTD |
PMID:31677563 PMID:35388968 |
|
NCBI chr 8:118,391,010...118,478,927
Ensembl chr 8:118,390,638...118,506,691
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
multiple interactions |
EXP |
glyphosate results in decreased expression of and results in increased phosphorylation of NFKBIA protein |
CTD |
PMID:35388968 |
|
NCBI chr 7:64,508,119...64,510,754
Ensembl chr 7:64,507,822...64,511,277
|
|
G |
NOS2 |
nitric oxide synthase 2 |
increases expression |
EXP |
glyphosate results in increased expression of NOS2 mRNA |
CTD |
PMID:35388968 |
|
NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,948...44,218,146
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
EXP |
glyphosate results in increased expression of NQO1 mRNA Betaine inhibits the reaction [glyphosate results in increased expression of NQO1 mRNA] |
CTD |
PMID:31677563 PMID:35388968 PMID:36584959 |
|
NCBI chr 6:17,292,962...17,302,593
Ensembl chr 6:17,292,770...17,302,590
|
|
G |
PCNA |
proliferating cell nuclear antigen |
increases expression multiple interactions |
EXP |
glyphosate results in increased expression of PCNA mRNA; glyphosate results in increased expression of PCNA protein Betaine inhibits the reaction [glyphosate results in increased expression of PCNA mRNA]; Betaine inhibits the reaction [glyphosate results in increased expression of PCNA protein] |
CTD |
PMID:36584959 |
|
NCBI chr17:14,137,746...14,142,584
Ensembl chr17:14,136,886...14,142,744
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
increases phosphorylation |
EXP |
glyphosate results in increased phosphorylation of RELA protein |
CTD |
PMID:35388968 |
|
NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469
|
|
G |
SDHA |
succinate dehydrogenase complex flavoprotein subunit A |
increases expression multiple interactions |
EXP |
glyphosate results in increased expression of SDHA mRNA Betaine inhibits the reaction [glyphosate results in increased expression of SDHA mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr16:79,838,442...79,862,956
Ensembl chr16:79,834,044...79,862,524
|
|
G |
SOD1 |
superoxide dismutase 1 |
decreases activity |
EXP |
glyphosate results in decreased activity of SOD1 protein |
CTD |
PMID:35388968 |
|
NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
|
|
G |
SOD2 |
superoxide dismutase 2 |
increases expression multiple interactions |
EXP |
glyphosate results in increased expression of SOD2 mRNA Betaine inhibits the reaction [glyphosate results in increased expression of SOD2 mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr 1:7,679,352...7,689,564
Ensembl chr 1:7,679,352...7,689,560
|
|
G |
SQSTM1 |
sequestosome 1 |
multiple interactions decreases expression |
EXP |
Acetylcysteine inhibits the reaction [glyphosate results in decreased expression of SQSTM1 protein] |
CTD |
PMID:35388968 |
|
NCBI chr 2:78,752,768...78,763,998
Ensembl chr 2:78,752,771...78,763,938
|
|
G |
TJP1 |
tight junction protein 1 |
decreases expression |
EXP |
glyphosate results in decreased expression of TJP1 mRNA |
CTD |
PMID:31677563 |
|
NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836
|
|
G |
TNF |
tumor necrosis factor |
affects secretion increases expression |
EXP |
glyphosate affects the secretion of TNF protein glyphosate results in increased expression of TNF protein |
CTD |
PMID:35388968 PMID:36584959 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
G |
UQCRB |
ubiquinol-cytochrome c reductase binding protein |
multiple interactions |
EXP |
[Betaine co-treated with glyphosate] results in decreased expression of UQCRB mRNA |
CTD |
PMID:36584959 |
|
NCBI chr 4:40,403,272...40,409,080
Ensembl chr 4:40,403,109...40,409,057
|
|
G |
XBP1 |
X-box binding protein 1 |
multiple interactions increases expression |
EXP |
Betaine inhibits the reaction [glyphosate results in increased expression of XBP1 mRNA] |
CTD |
PMID:36584959 |
|
NCBI chr14:46,011,239...46,016,526
Ensembl chr14:46,008,377...46,016,526
|
|
|
G |
NOS3 |
nitric oxide synthase 3 |
decreases expression multiple interactions |
EXP |
Ibuprofen results in decreased expression of NOS3 mRNA 11-deoxy-16-phenoxy-17,18,19,20-tetranorprostaglandin E1 inhibits the reaction [Ibuprofen results in decreased expression of NOS3 mRNA]; 11-deoxyprostaglandin E1 inhibits the reaction [Ibuprofen results in decreased expression of NOS3 mRNA]; 16,16-Dimethylprostaglandin E2 inhibits the reaction [Ibuprofen results in decreased expression of NOS3 mRNA]; sulprostone inhibits the reaction [Ibuprofen results in decreased expression of NOS3 mRNA] |
CTD |
PMID:10525081 PMID:10644584 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
|
G |
KNG1 |
kininogen 1 |
decreases activity |
EXP |
icatibant results in decreased activity of KNG1 protein modified form |
CTD |
PMID:7890486 |
|
NCBI chr13:124,521,276...124,557,384
Ensembl chr13:124,521,340...124,557,958
|
|
|
G |
AGT |
angiotensinogen |
affects activity |
EXP |
Indomethacin affects the activity of AGT protein |
CTD |
PMID:21127344 |
|
NCBI chr14:59,643,030...59,656,835
Ensembl chr14:59,643,292...59,656,833
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
increases expression |
EXP |
Indomethacin results in increased expression of DDIT3 mRNA |
CTD |
PMID:18799549 |
|
NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
EXP |
Indomethacin results in increased expression of HSPA5 mRNA |
CTD |
PMID:18799549 |
|
NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
|
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
EXP |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of CXCL8 protein |
CTD |
PMID:15912099 |
|
NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861
|
|
|
G |
CYP2C49 |
cytochrome P450 2C49 |
decreases response to substance |
EXP |
CYP2C49 protein results in decreased susceptibility to isoxaben |
CTD |
PMID:16315095 |
|
NCBI chr14:106,571,803...106,612,082
Ensembl chr14:106,285,173...106,612,455
|
|
|
G |
COL4A2 |
collagen type IV alpha 2 chain |
multiple interactions decreases expression |
EXP |
KT 5823 inhibits the reaction [NOC 18 results in increased expression of COL4A2 protein] KT 5823 results in decreased expression of COL4A2 protein |
CTD |
PMID:21307347 |
|
NCBI chr11:76,996,885...77,161,617
Ensembl chr11:76,997,516...77,161,614
|
|
G |
COL4A3 |
collagen type IV alpha 3 chain |
decreases expression multiple interactions |
EXP |
KT 5823 results in decreased expression of COL4A3 mRNA KT 5823 inhibits the reaction [NOC 18 results in increased expression of COL4A3 mRNA] |
CTD |
PMID:21307347 |
|
NCBI chr15:128,611,640...128,763,331
Ensembl chr15:128,611,866...128,763,122
|
|
G |
ITGAV |
integrin subunit alpha V |
multiple interactions |
EXP |
KT 5823 inhibits the reaction [NOC 18 results in increased expression of [ITGAV protein binds to ITGB3 protein]] |
CTD |
PMID:21307347 |
|
NCBI chr15:91,604,666...91,711,843
Ensembl chr15:91,604,676...91,711,851
|
|
G |
ITGB3 |
integrin subunit beta 3 |
multiple interactions |
EXP |
KT 5823 inhibits the reaction [NOC 18 results in increased expression of [ITGAV protein binds to ITGB3 protein]] |
CTD |
PMID:21307347 |
|
NCBI chr12:16,694,466...16,752,228
Ensembl chr12:16,693,514...16,752,292
|
|
|
G |
ALPL |
alkaline phosphatase, biomineralization associated |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA |
CTD |
PMID:30481989 |
|
NCBI chr 6:79,589,695...79,649,646
Ensembl chr 6:79,589,045...79,649,644
|
|
G |
BCL2L1 |
BCL2 like 1 |
multiple interactions |
EXP |
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of BCL2L1 mRNA |
CTD |
PMID:30481989 |
|
NCBI chr17:35,366,139...35,415,798
Ensembl chr17:35,366,143...35,414,694
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
[Troglitazone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CASP3 mRNA |
CTD |
PMID:30481989 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CEBPA |
CCAAT enhancer binding protein alpha |
multiple interactions |
EXP |
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CEBPA mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CEBPA mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr 6:43,083,200...43,085,884
Ensembl chr 6:43,083,207...43,085,836
|
|
G |
COL1A1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL1A1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL1A1 mRNA |
CTD |
PMID:30481989 |
|
NCBI chr12:26,379,087...26,397,180
Ensembl chr12:26,379,090...26,397,004
|
|
G |
CTNNB1 |
catenin beta 1 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr13:25,163,550...25,208,314
Ensembl chr13:25,164,277...25,208,311
|
|
G |
FABP4 |
fatty acid binding protein 4 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr 4:55,096,400...55,101,209
Ensembl chr 4:55,096,404...55,101,896
|
|
G |
IGF1 |
insulin like growth factor 1 |
multiple interactions |
EXP |
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1 mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr 5:81,762,027...81,909,253
Ensembl chr 5:81,775,970...81,848,033
|
|
G |
IGF1R |
insulin like growth factor 1 receptor |
multiple interactions |
EXP |
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1R mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1R mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr 1:137,383,623...137,691,038
Ensembl chr 1:137,387,825...137,691,058
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,322...68,433,944
|
|
G |
RUNX2 |
RUNX family transcription factor 2 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA |
CTD |
PMID:30481989 |
|
NCBI chr 7:40,106,581...40,353,304
Ensembl chr 7:40,106,532...40,460,687
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr 8:131,077,786...131,085,334
Ensembl chr 8:131,077,786...131,085,340
|
|
|
G |
BMP2 |
bone morphogenetic protein 2 |
multiple interactions |
EXP |
leptomycin B inhibits the reaction [Warfarin results in increased expression of BMP2 mRNA] |
CTD |
PMID:34520801 |
|
NCBI chr17:15,750,487...15,762,982
Ensembl chr17:15,749,835...15,761,195
|
|
|
G |
ANXA5 |
annexin A5 |
multiple interactions increases activity |
EXP |
Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]]; TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]]] |
CTD |
PMID:10617950 |
|
NCBI chr 8:102,387,833...102,420,868
Ensembl chr 8:102,388,103...102,425,750
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases activity |
EXP |
Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]; TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]; Zinc Acetate inhibits the reaction [Linoleic Acid results in increased activity of CASP3 protein]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]; Zinc Acetate promotes the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]] |
CTD |
PMID:10617950 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
IL6 |
interleukin 6 |
increases expression multiple interactions |
EXP |
Linoleic Acid results in increased expression of IL6 mRNA; Linoleic Acid results in increased expression of IL6 protein 2,4-thiazolidinedione inhibits the reaction [Linoleic Acid results in increased expression of IL6 protein]; PPARG protein promotes the reaction [Linoleic Acid results in increased expression of IL6 protein]; Quercetin inhibits the reaction [Linoleic Acid results in increased expression of IL6 mRNA] |
CTD |
PMID:14519784 PMID:15051824 |
|
NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions increases activity |
EXP |
PPARG protein promotes the reaction [Linoleic Acid results in increased activity of RELA protein]; PPARG protein promotes the reaction [Linoleic Acid results in increased expression of IL6 protein]; Quercetin inhibits the reaction [Linoleic Acid results in increased activity of PPARG protein]; Vitamin E inhibits the reaction [Linoleic Acid results in increased activity of PPARG protein] |
CTD |
PMID:14519784 PMID:15051824 |
|
NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,322...68,433,944
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
EXP |
Linoleic Acid results in increased expression of PTGS2 mRNA Linoleic Acid promotes the reaction [[Polychlorinated Biphenyls results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Linoleic Acid promotes the reaction [Polychlorinated Biphenyls results in increased expression of PTGS2 mRNA]; Linoleic Acid promotes the reaction [Polychlorinated Biphenyls results in increased expression of PTGS2 protein]; Polychlorinated Biphenyls promotes the reaction [[Linoleic Acid results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; prolinedithiocarbamate inhibits the reaction [[Linoleic Acid co-treated with Polychlorinated Biphenyls] results in increased expression of PTGS2 mRNA]; prolinedithiocarbamate inhibits the reaction [Linoleic Acid results in increased expression of PTGS2 mRNA] |
CTD |
PMID:18155686 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases activity |
EXP |
2,4-thiazolidinedione inhibits the reaction [Linoleic Acid results in increased activity of RELA protein]; PPARG protein promotes the reaction [Linoleic Acid results in increased activity of RELA protein] |
CTD |
PMID:14519784 |
|
NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]; Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]; TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]; TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of ANXA5 protein]]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [Linoleic Acid promotes the reaction [TNF protein results in increased activity of CASP3 protein]]]; Zinc Acetate inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of ANXA5 protein]]]; Zinc Acetate promotes the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine promotes the reaction [TNF protein promotes the reaction [Linoleic Acid results in increased activity of CASP3 protein]]] |
CTD |
PMID:10617950 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
increases expression multiple interactions |
EXP |
Linoleic Acid results in increased expression of VCAM1 mRNA [Linoleic Acid co-treated with Polychlorinated Biphenyls] results in increased expression of VCAM1 protein; Linoleic Acid promotes the reaction [Polychlorinated Biphenyls results in increased expression of VCAM1 mRNA]; prolinedithiocarbamate inhibits the reaction [Linoleic Acid results in increased expression of VCAM1 mRNA]; Quercetin inhibits the reaction [Linoleic Acid results in increased expression of VCAM1 mRNA] |
CTD |
PMID:15051824 PMID:18155686 |
|
NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,920...117,511,222
|
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein] |
CTD |
PMID:24512358 |
|
NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183
|
|
|
G |
ACHE |
acetylcholinesterase |
increases activity |
EXP |
Lithocholic Acid results in increased activity of ACHE protein |
CTD |
PMID:3697337 |
|
NCBI chr 3:8,732,451...8,738,274
Ensembl chr 3:8,732,441...8,738,605
|
|
G |
LRP2 |
LDL receptor related protein 2 |
affects expression multiple interactions |
EXP |
Lithocholic Acid affects the expression of LRP2 protein Lithocholic Acid binds to and results in increased activity of LRP2 protein |
CTD |
PMID:15375181 |
|
NCBI chr15:75,565,299...75,754,604
Ensembl chr15:75,565,303...75,716,694
|
|
|
G |
AKT2 |
AKT serine/threonine kinase 2 |
increases expression |
EXP |
Malathion results in increased expression of AKT2 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 6:48,555,785...48,620,472
Ensembl chr 6:48,555,795...48,587,919
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
Malathion results in increased expression of BAX mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression multiple interactions |
EXP |
Malathion results in decreased expression of BCL2 mRNA Melatonin inhibits the reaction [Malathion results in decreased expression of BCL2 mRNA] |
CTD |
PMID:31535366 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
CAT |
catalase |
decreases expression multiple interactions |
EXP |
Malathion results in decreased expression of CAT mRNA Melatonin inhibits the reaction [Malathion results in decreased expression of CAT mRNA] |
CTD |
PMID:31535366 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
decreases expression |
EXP |
Malathion results in decreased expression of CYP1A1 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,802,887...58,809,775
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
decreases expression |
EXP |
Malathion results in decreased expression of CYP1B1 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 3:102,195,743...102,205,687
Ensembl chr 3:102,195,741...102,205,683
|
|
G |
DUOX2 |
dual oxidase 2 |
decreases expression |
EXP |
Malathion results in decreased expression of DUOX2 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 1:126,620,468...126,641,406
Ensembl chr 1:126,620,510...126,641,406
|
|
G |
GPX4 |
glutathione peroxidase 4 |
increases expression |
EXP |
Malathion results in increased expression of GPX4 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 2:77,321,568...77,323,931
Ensembl chr 2:77,320,464...77,323,931
|
|
G |
GPX6 |
glutathione peroxidase 6 |
increases expression |
EXP |
Malathion results in increased expression of GPX6 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 7:22,256,013...22,267,992
Ensembl chr 7:22,256,038...22,267,992
|
|
G |
LOC106504562 |
glutathione S-transferase alpha M14 |
decreases expression |
EXP |
Malathion results in decreased expression of GSTA1 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 7:46,553,813...46,567,596
|
|
G |
MT-CO1 |
mitochondrially encoded cytochrome c oxidase I |
affects expression |
EXP |
Malathion affects the expression of COX1 mRNA |
CTD |
PMID:17454254 |
|
NCBI chr MT:6,511...8,055
Ensembl chr MT:6,511...8,055
|
|
G |
MT-CO3 |
mitochondrially encoded cytochrome c oxidase III |
affects expression |
EXP |
Malathion affects the expression of COX3 mRNA |
CTD |
PMID:17454254 |
|
NCBI chr MT:9,800...10,583
Ensembl chr MT:9,800...10,583
|
|
G |
PLIN2 |
perilipin 2 |
multiple interactions decreases expression |
EXP |
Melatonin inhibits the reaction [Malathion results in decreased expression of PLIN2 mRNA]; Melatonin inhibits the reaction [Malathion results in decreased expression of PLIN2 protein] Malathion results in decreased expression of PLIN2 mRNA; Malathion results in decreased expression of PLIN2 protein |
CTD |
PMID:31535366 |
|
NCBI chr 1:203,683,867...203,709,277
Ensembl chr 1:203,683,862...203,709,273
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions decreases expression |
EXP |
Melatonin inhibits the reaction [Malathion results in decreased expression of PPARG mRNA]; Melatonin inhibits the reaction [Malathion results in decreased expression of PPARG protein] Malathion results in decreased expression of PPARG mRNA; Malathion results in decreased expression of PPARG protein |
CTD |
PMID:31535366 |
|
NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,322...68,433,944
|
|
G |
SLC34A2 |
solute carrier family 34 member 2 |
increases expression |
EXP |
Malathion results in increased expression of SLC34A2 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 8:19,481,127...19,507,903
Ensembl chr 8:19,481,198...19,509,666
|
|
G |
SOD2 |
superoxide dismutase 2 |
increases expression |
EXP |
Malathion results in increased expression of SOD2 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 1:7,679,352...7,689,564
Ensembl chr 1:7,679,352...7,689,560
|
|
G |
SORD |
sorbitol dehydrogenase |
increases expression |
EXP |
Malathion results in increased expression of SORD mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 1:126,659,198...126,701,084
Ensembl chr 1:126,655,156...126,701,138
|
|
G |
TP53 |
tumor protein p53 |
increases expression multiple interactions |
EXP |
Malathion results in increased expression of TP53 mRNA Melatonin inhibits the reaction [Malathion results in increased expression of TP53 mRNA] |
CTD |
PMID:31535366 |
|
NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818
|
|
|
G |
ACO2 |
aconitase 2 |
multiple interactions decreases activity |
EXP |
Curcumin inhibits the reaction [maleic acid results in decreased activity of ACO2 protein] |
CTD |
PMID:25119790 |
|
NCBI chr 5:7,014,383...7,071,023
Ensembl chr 5:7,008,719...7,071,025
|
|
|
G |
CAT |
catalase |
multiple interactions |
EXP |
CAT protein inhibits the reaction [4-xylene results in increased secretion of Malondialdehyde]; CAT protein inhibits the reaction [Toluene results in increased secretion of Malondialdehyde] |
CTD |
PMID:12781212 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
|
G |
SELE |
selectin E |
increases expression |
EXP |
mastoparan results in increased expression of SELE mRNA |
CTD |
PMID:10769290 |
|
NCBI chr 4:81,289,061...81,299,657
|
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of BAX protein] |
CTD |
PMID:35665993 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions increases expression |
EXP |
Melatonin inhibits the reaction [Malathion results in decreased expression of BCL2 mRNA] Melatonin results in increased expression of BCL2 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
CASP3 |
caspase 3 |
decreases expression multiple interactions |
EXP |
Melatonin results in decreased expression of CASP3 mRNA Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of CASP3 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of CASP3 protein] |
CTD |
PMID:31535366 PMID:35665993 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CASP8 |
caspase 8 |
multiple interactions |
EXP |
Melatonin inhibits the reaction [tetrabromobisphenol A results in decreased expression of CASP8 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in decreased expression of CASP8 protein] |
CTD |
PMID:35665993 |
|
NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
EXP |
Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of CASP9 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of CASP9 protein] |
CTD |
PMID:35665993 |
|
NCBI chr 6:74,707,597...74,730,033
Ensembl chr 6:74,706,516...74,730,007
|
|
G |
CAT |
catalase |
multiple interactions |
EXP |
Melatonin inhibits the reaction [Malathion results in decreased expression of CAT mRNA] |
CTD |
PMID:31535366 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
COX7A2L |
cytochrome c oxidase subunit 7A2 like |
multiple interactions |
EXP |
Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of COX7A2L mRNA] |
CTD |
PMID:35665993 |
|
NCBI chr 3:97,951,115...97,983,309
Ensembl chr 3:97,951,114...97,983,309
|
|
G |
GPX4 |
glutathione peroxidase 4 |
increases expression |
EXP |
Melatonin results in increased expression of GPX4 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 2:77,321,568...77,323,931
Ensembl chr 2:77,320,464...77,323,931
|
|
G |
MLKL |
mixed lineage kinase domain like pseudokinase |
multiple interactions |
EXP |
Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of MLKL mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of MLKL protein] |
CTD |
PMID:35665993 |
|
NCBI chr 6:12,923,846...12,951,176
Ensembl chr 6:12,924,894...12,951,173
|
|
G |
PLIN2 |
perilipin 2 |
multiple interactions |
EXP |
Melatonin inhibits the reaction [Malathion results in decreased expression of PLIN2 mRNA]; Melatonin inhibits the reaction [Malathion results in decreased expression of PLIN2 protein] |
CTD |
PMID:31535366 |
|
NCBI chr 1:203,683,867...203,709,277
Ensembl chr 1:203,683,862...203,709,273
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions |
EXP |
Melatonin inhibits the reaction [Malathion results in decreased expression of PPARG mRNA]; Melatonin inhibits the reaction [Malathion results in decreased expression of PPARG protein] |
CTD |
PMID:31535366 |
|
NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,322...68,433,944
|
|
G |
PTEN |
phosphatase and tensin homolog |
multiple interactions |
EXP |
Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of PTEN mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of PTEN protein] |
CTD |
PMID:35665993 |
|
NCBI chr14:99,929,590...100,021,619
|
|
G |
RIPK1 |
receptor interacting serine/threonine kinase 1 |
multiple interactions |
EXP |
Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of RIPK1 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of RIPK1 protein] |
CTD |
PMID:35665993 |
|
NCBI chr 7:1,841,143...1,880,705
Ensembl chr 7:1,841,239...1,880,699
|
|
G |
RIPK3 |
receptor interacting serine/threonine kinase 3 |
multiple interactions |
EXP |
Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of RIPK3 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of RIPK3 protein] |
CTD |
PMID:35665993 |
|
NCBI chr 7:74,951,145...74,955,255
Ensembl chr 7:74,951,145...74,955,251
|
|
G |
SOD2 |
superoxide dismutase 2 |
increases expression |
EXP |
Melatonin results in increased expression of SOD2 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr 1:7,679,352...7,689,564
Ensembl chr 1:7,679,352...7,689,560
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions decreases expression |
EXP |
Melatonin inhibits the reaction [Malathion results in increased expression of TP53 mRNA] Melatonin results in decreased expression of TP53 mRNA |
CTD |
PMID:31535366 |
|
NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818
|
|
|
G |
IL4 |
interleukin 4 |
decreases response to substance |
EXP |
IL4 protein results in decreased susceptibility to Melitten |
CTD |
PMID:20017192 |
|
NCBI chr 2:134,986,817...134,994,365
Ensembl chr 2:134,986,817...134,994,365
|
|
G |
PLA2G1B |
phospholipase A2 group IB |
increases activity |
EXP |
Melitten results in increased activity of PLA2G1B protein |
CTD |
PMID:9092818 |
|
NCBI chr14:40,314,520...40,322,315
Ensembl chr14:40,314,520...40,322,315
|
|
G |
SELE |
selectin E |
increases expression |
EXP |
Melitten results in increased expression of SELE mRNA |
CTD |
PMID:10769290 |
|
NCBI chr 4:81,289,061...81,299,657
|
|
|
G |
GPD1 |
glycerol-3-phosphate dehydrogenase 1 |
increases activity |
EXP |
Methoprene results in increased activity of GPD1 protein |
CTD |
PMID:15583048 |
|
NCBI chr 5:16,008,179...16,021,676
Ensembl chr 5:16,007,448...16,017,825
|
|
|
G |
CHRM2 |
cholinergic receptor muscarinic 2 |
multiple interactions affects binding |
EXP |
[N-Methylscopolamine binds to CHRM2 protein] affects the reaction [1,3-bis(4-(phthalimidomethoxyiminomethyl)pyridinium-1-yl)propane binds to CHRM2 protein]; brucine analog promotes the reaction [N-Methylscopolamine binds to CHRM2 protein]; Strychnine analog promotes the reaction [N-Methylscopolamine binds to CHRM2 protein] |
CTD |
PMID:12757728 PMID:16362429 |
|
NCBI chr18:12,455,139...12,600,314
Ensembl chr18:12,455,145...12,600,186
|
|
|
G |
GOT1 |
glutamic-oxaloacetic transaminase 1 |
affects glycation affects folding decreases activity |
EXP |
Pyruvaldehyde affects the glycation of GOT1 protein Pyruvaldehyde affects the folding of GOT1 protein Pyruvaldehyde results in decreased activity of GOT1 protein |
CTD |
PMID:12559987 |
|
NCBI chr14:110,608,422...110,635,825
Ensembl chr14:110,608,430...110,635,874
|
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein]; Acetylcysteine inhibits the reaction [Cadmium results in increased expression of BAX protein] |
CTD |
PMID:19135140 PMID:33905761 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
EXP |
[Acetylcysteine co-treated with fumonisin B1 co-treated with deoxynivalenol] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with fumonisin B1] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with Zearalenone co-treated with deoxynivalenol] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with Zearalenone] results in increased expression of BCL2 protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [Cadmium results in decreased expression of BCL2 protein]; Acetylcysteine inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in decreased expression of BCL2 mRNA]] |
CTD |
PMID:19135140 PMID:29109043 PMID:33905761 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
BMP15 |
bone morphogenetic protein 15 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Zearalenone results in decreased expression of BMP15 mRNA] |
CTD |
PMID:26386189 |
|
NCBI chr X:44,613,122...44,620,575
Ensembl chr X:44,613,122...44,620,575
|
|
G |
CASP1 |
caspase 1, apoptosis-related cysteine peptidase |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein] |
CTD |
PMID:36281498 |
|
NCBI chr 9:35,188,066...35,199,364
Ensembl chr 9:35,186,420...35,200,328
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
[Acetylcysteine co-treated with Zearalenone] results in decreased expression of CASP3 protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 protein]; Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein]; Acetylcysteine inhibits the reaction [Cadmium results in increased activity of CASP3 protein]; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [deoxynivalenol results in increased expression of CASP3 protein]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]] |
CTD |
PMID:17383151 PMID:19135140 PMID:29109043 PMID:33905761 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein]; Acetylcysteine inhibits the reaction [Cadmium results in increased activity of CASP9 protein] |
CTD |
PMID:19135140 PMID:33905761 |
|
NCBI chr 6:74,707,597...74,730,033
Ensembl chr 6:74,706,516...74,730,007
|
|
G |
CAT |
catalase |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of CAT mRNA] |
CTD |
PMID:36281498 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
CCL2 |
chemokine (C-C motif) ligand 2 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA] |
CTD |
PMID:19265715 |
|
NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026
|
|
G |
CYCS |
cytochrome c, somatic |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [[Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA]]; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA]] |
CTD |
PMID:29109043 |
|
NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased expression of DDIT3 mRNA] |
CTD |
PMID:18086661 |
|
NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased expression of FOS mRNA] |
CTD |
PMID:18086661 |
|
NCBI chr 7:98,449,508...98,451,971
Ensembl chr 7:98,449,349...98,455,554
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA] |
CTD |
PMID:36281498 |
|
NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
|
|
G |
GPX4 |
glutathione peroxidase 4 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of GPX4 mRNA] |
CTD |
PMID:36281498 |
|
NCBI chr 2:77,321,568...77,323,931
Ensembl chr 2:77,320,464...77,323,931
|
|
G |
GSDMD |
gasdermin D |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein] |
CTD |
PMID:36281498 |
|
NCBI chr 4:995,753...1,001,964
Ensembl chr 4:995,763...1,000,271
|
|
G |
GSR |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]] |
CTD |
PMID:29109043 |
|
NCBI chr15:54,382,564...54,433,989
Ensembl chr15:54,382,567...54,433,984
|
|
G |
HSP90B1 |
heat shock protein 90 beta family member 1 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased expression of HSP90B1 mRNA] |
CTD |
PMID:18086661 |
|
NCBI chr 5:80,511,513...80,531,016
Ensembl chr 5:80,511,506...80,530,991
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased expression of HSPA5 mRNA] |
CTD |
PMID:18086661 |
|
NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
|
|
G |
LOC110258578 |
interleukin-1 beta-like |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of IL1B protein] |
CTD |
PMID:36281498 |
|
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:17383151 |
|
NCBI chr14:88,988,914...89,108,875
Ensembl chr14:88,988,949...89,108,874
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:17383151 |
|
NCBI chr 2:78,338,466...78,399,108
Ensembl chr 2:78,338,376...78,399,100
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Cisplatin results in increased expression of MYC] |
CTD |
PMID:12712633 |
|
NCBI chr 4:12,455,141...12,460,360
Ensembl chr 4:12,455,122...12,461,078
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein] |
CTD |
PMID:24512358 |
|
NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183
|
|
G |
NLRP3 |
NLR family pyrin domain containing 3 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of NLRP3 protein] |
CTD |
PMID:36281498 |
|
NCBI chr 2:56,892,241...56,977,412
Ensembl chr 2:56,892,243...56,977,228
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of INOS mRNA] |
CTD |
PMID:36281498 |
|
NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,948...44,218,146
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of PTGS2 mRNA] |
CTD |
PMID:36281498 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
G |
PTX3 |
pentraxin 3 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Zearalenone results in decreased expression of PTX3 mRNA] |
CTD |
PMID:26386189 |
|
NCBI chr13:97,273,594...97,279,570
Ensembl chr13:97,273,594...97,279,569
|
|
G |
PYCARD |
PYD and CARD domain containing |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of PYCARD protein] |
CTD |
PMID:36281498 |
|
NCBI chr 3:17,305,921...17,307,521
Ensembl chr 3:17,306,099...17,307,786
|
|
G |
SQSTM1 |
sequestosome 1 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [glyphosate results in decreased expression of SQSTM1 protein] |
CTD |
PMID:35388968 |
|
NCBI chr 2:78,752,768...78,763,998
Ensembl chr 2:78,752,771...78,763,938
|
|
G |
TNFAIP6 |
TNF alpha induced protein 6 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Zearalenone results in decreased expression of TNFAIP6 mRNA] |
CTD |
PMID:26386189 |
|
NCBI chr15:862,013...881,352
Ensembl chr15:862,015...881,461
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in increased expression of TP53 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 results in increased expression of TP53 mRNA]]; Acetylcysteine promotes the reaction [deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA]] |
CTD |
PMID:29109043 |
|
NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818
|
|
G |
ZP3 |
zona pellucida glycoprotein 3 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Zearalenone results in decreased expression of ZP3 mRNA] |
CTD |
PMID:26386189 |
|
NCBI chr 3:9,934,760...9,944,924
Ensembl chr 3:9,934,761...9,944,941
|
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
increases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of AKT1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in increased degradation of AKT1 protein] |
CTD |
PMID:16239170 |
|
|
|
G |
CLIC5 |
chloride intracellular channel 5 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Cadmium Chloride results in decreased expression of CLIC5 protein] |
CTD |
PMID:20576581 |
|
NCBI chr 7:40,683,044...40,808,017
Ensembl chr 7:40,682,907...40,863,886
|
|
G |
LRP2 |
LDL receptor related protein 2 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Cadmium Chloride results in decreased expression of LRP2 protein] |
CTD |
PMID:20576581 |
|
NCBI chr15:75,565,299...75,754,604
Ensembl chr15:75,565,303...75,716,694
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in increased degradation of NOS3 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NOS3 protein |
CTD |
PMID:16239170 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
|
G |
FOXO1 |
forkhead box O1 |
increases expression |
EXP |
Niacinamide results in increased expression of FOXO1 mRNA |
CTD |
PMID:17851734 |
|
NCBI chr11:15,317,222...15,410,059
Ensembl chr11:15,317,124...15,410,473
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
increases expression |
EXP |
Niacinamide results in increased expression of PPARG mRNA |
CTD |
PMID:17851734 |
|
NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,322...68,433,944
|
|
G |
SIRT1 |
sirtuin 1 |
decreases expression |
EXP |
Niacinamide results in decreased expression of SIRT1 mRNA |
CTD |
PMID:17851734 |
|
NCBI chr14:71,091,167...71,126,351
Ensembl chr14:71,091,167...71,123,297
|
|
|
G |
CYP2C49 |
cytochrome P450 2C49 |
multiple interactions |
EXP |
CYP2C49 protein results in increased metabolism of and results in decreased susceptibility to norflurazone |
CTD |
PMID:16315095 |
|
NCBI chr14:106,571,803...106,612,082
Ensembl chr14:106,285,173...106,612,455
|
|
|
G |
SLC22A5 |
solute carrier family 22 member 5 |
increases uptake |
EXP |
SLC22A5 protein results in increased uptake of Acetylcarnitine |
CTD |
PMID:16826461 |
|
NCBI chr 2:134,660,741...134,847,575
Ensembl chr 2:134,660,808...134,686,219
|
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
EXP |
ochratoxin A results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:30287338 |
|
|
|
G |
ANXA5 |
annexin A5 |
decreases expression |
EXP |
ochratoxin A results in decreased expression of ANXA5 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 8:102,387,833...102,420,868
Ensembl chr 8:102,388,103...102,425,750
|
|
G |
APAF1 |
apoptotic peptidase activating factor 1 |
increases expression multiple interactions |
EXP |
ochratoxin A results in increased expression of APAF1 mRNA; ochratoxin A results in increased expression of APAF1 protein fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of APAF1 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of APAF1 protein] |
CTD |
PMID:36397609 |
|
NCBI chr 5:85,166,616...85,258,751
Ensembl chr 5:85,166,628...85,258,364
|
|
G |
ATG5 |
autophagy related 5 |
multiple interactions increases expression |
EXP |
ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein] ochratoxin A results in increased expression of ATG5 protein |
CTD |
PMID:28699257 PMID:30287338 |
|
NCBI chr 1:72,343,950...72,520,402
Ensembl chr 1:72,270,799...72,520,396
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP |
[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of BAX mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of BAX protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of BAX mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA] ochratoxin A results in increased expression of BAX mRNA; ochratoxin A results in increased expression of BAX protein |
CTD |
PMID:33905761 PMID:36397609 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions decreases expression affects expression |
EXP |
[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in decreased expression of BCL2 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in decreased expression of BCL2 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in decreased expression of BCL2 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; TLR4 protein affects the reaction [ochratoxin A affects the expression of BCL2 mRNA] ochratoxin A results in decreased expression of BCL2 mRNA; ochratoxin A results in decreased expression of BCL2 protein |
CTD |
PMID:28528741 PMID:29080797 PMID:33905761 PMID:36397609 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
BECN1 |
beclin 1 |
multiple interactions increases expression |
EXP |
BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein] ochratoxin A results in increased expression of BECN1 protein |
CTD |
PMID:30287338 |
|
NCBI chr12:20,041,914...20,054,249
Ensembl chr12:20,041,956...20,054,373
|
|
G |
BRCA1 |
BRCA1 DNA repair associated |
increases expression |
EXP |
ochratoxin A results in increased expression of BRCA1 protein |
CTD |
PMID:32454083 |
|
NCBI chr12:19,788,087...19,854,515
Ensembl chr12:19,786,020...19,854,668
|
|
G |
CASP1 |
caspase 1, apoptosis-related cysteine peptidase |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein]; ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein; Taurine inhibits the reaction [ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein] |
CTD |
PMID:36281498 |
|
NCBI chr 9:35,188,066...35,199,364
Ensembl chr 9:35,186,420...35,200,328
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases expression increases cleavage |
EXP |
3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; Chloroquine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 protein modified form]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 protein modified form]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein] ochratoxin A results in increased expression of CASP3 mRNA; ochratoxin A results in increased expression of CASP3 protein; ochratoxin A results in increased expression of CASP3 protein modified form |
CTD |
PMID:30287338 PMID:33905761 PMID:36397609 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CASP9 |
caspase 9 |
multiple interactions increases expression |
EXP |
[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 protein modified form]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 protein modified form]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein] ochratoxin A results in increased expression of CASP9 mRNA; ochratoxin A results in increased expression of CASP9 protein; ochratoxin A results in increased expression of CASP9 protein modified form |
CTD |
PMID:33905761 PMID:36397609 |
|
NCBI chr 6:74,707,597...74,730,033
Ensembl chr 6:74,706,516...74,730,007
|
|
G |
CAT |
catalase |
decreases expression multiple interactions |
EXP |
ochratoxin A results in decreased expression of CAT mRNA; ochratoxin A results in decreased expression of CAT protein Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of CAT mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of CAT mRNA] |
CTD |
PMID:18547704 PMID:36281498 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
CRYAB |
crystallin alpha B |
increases expression |
EXP |
ochratoxin A results in increased expression of CRYAB mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 9:39,638,505...39,643,530
Ensembl chr 9:39,638,506...39,643,530
|
|
G |
CYCS |
cytochrome c, somatic |
multiple interactions increases expression |
EXP |
fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CYCS mRNA] |
CTD |
PMID:36397609 |
|
NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
|
|
G |
CYP2G2 |
cytochrome P450 family 2 subfamily G member 2 |
decreases expression |
EXP |
ochratoxin A results in decreased expression of CYP2A6 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 6:49,069,613...49,084,953
|
|
G |
DAD1 |
defender against cell death 1 |
decreases expression |
EXP |
ochratoxin A results in decreased expression of DAD1 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 7:76,432,040...76,457,403
Ensembl chr 7:76,432,051...76,457,192
|
|
G |
DNMT1 |
DNA methyltransferase 1 |
increases expression multiple interactions |
EXP |
ochratoxin A results in increased expression of DNMT1 mRNA; ochratoxin A results in increased expression of DNMT1 protein Decitabine inhibits the reaction [ochratoxin A results in increased expression of DNMT1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in increased expression of DNMT1 protein] |
CTD |
PMID:29080797 PMID:30923867 |
|
NCBI chr 2:68,981,564...69,040,364
Ensembl chr 2:68,981,566...69,029,844
|
|
G |
DNMT3A |
DNA methyltransferase 3 alpha |
increases expression |
EXP |
ochratoxin A results in increased expression of DNMT3A mRNA |
CTD |
PMID:29080797 PMID:30923867 |
|
NCBI chr 3:113,501,972...113,609,148
Ensembl chr 3:113,528,926...113,603,087
|
|
G |
GCLC |
glutamate-cysteine ligase catalytic subunit |
decreases expression multiple interactions |
EXP |
ochratoxin A results in decreased expression of GCLC mRNA ochratoxin A inhibits the reaction [sulforaphane results in increased expression of GCLC mRNA] |
CTD |
PMID:18547363 |
|
NCBI chr 7:27,209,565...27,253,535
Ensembl chr 7:27,209,565...27,253,530
|
|
G |
GLMN |
glomulin, FKBP associated protein |
increases expression |
EXP |
ochratoxin A results in increased expression of GLMN mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 4:124,773,957...124,813,336
Ensembl chr 4:124,773,980...124,813,335
|
|
G |
GPX1 |
glutathione peroxidase 1 |
decreases expression multiple interactions |
EXP |
ochratoxin A results in decreased expression of GPX1 mRNA Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA] |
CTD |
PMID:36281498 |
|
NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
|
|
G |
GPX4 |
glutathione peroxidase 4 |
decreases expression multiple interactions |
EXP |
ochratoxin A results in decreased expression of GPX4 mRNA Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of GPX4 mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of GPX4 mRNA] |
CTD |
PMID:36281498 |
|
NCBI chr 2:77,321,568...77,323,931
Ensembl chr 2:77,320,464...77,323,931
|
|
G |
GSDMD |
gasdermin D |
multiple interactions increases expression |
EXP |
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein] |
CTD |
PMID:36281498 |
|
NCBI chr 4:995,753...1,001,964
Ensembl chr 4:995,763...1,000,271
|
|
G |
H2AX |
H2A.X variant histone |
multiple interactions increases expression |
EXP |
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in increased expression of H2AX protein]; Decitabine inhibits the reaction [ochratoxin A results in increased expression of H2AX protein]; STAT3 protein affects the reaction [ochratoxin A results in increased expression of H2AX protein] |
CTD |
PMID:30923867 PMID:32454083 |
|
NCBI chr 9:46,308,824...46,310,494
Ensembl chr 9:46,309,653...46,310,084
|
|
G |
HAVCR1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
EXP |
[fumonisin B1 co-treated with ochratoxin A] results in increased expression of HAVCR1 mRNA |
CTD |
PMID:33905761 |
|
NCBI chr16:66,162,318...66,208,868
|
|
G |
HDAC1 |
histone deacetylase 1 |
multiple interactions increases expression |
EXP |
Panobinostat inhibits the reaction [ochratoxin A results in increased expression of HDAC1 mRNA]; Panobinostat inhibits the reaction [ochratoxin A results in increased expression of HDAC1 protein] ochratoxin A results in increased expression of HDAC1 mRNA; ochratoxin A results in increased expression of HDAC1 protein |
CTD |
PMID:29080797 |
|
NCBI chr 6:88,749,611...88,785,220
Ensembl chr 6:88,749,634...88,785,411
|
|
G |
HSP90B1 |
heat shock protein 90 beta family member 1 |
increases expression decreases expression |
EXP |
ochratoxin A results in increased expression of HSP90B1 mRNA ochratoxin A results in decreased expression of HSP90B1 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 5:80,511,513...80,531,016
Ensembl chr 5:80,511,506...80,530,991
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
EXP |
ochratoxin A results in increased expression of HSPA5 mRNA; ochratoxin A results in increased expression of HSPA5 protein |
CTD |
PMID:28699257 |
|
NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
|
|
G |
HSPD1 |
heat shock protein family D (Hsp60) member 1 |
decreases expression |
EXP |
ochratoxin A results in decreased expression of HSPD1 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr15:101,360,355...101,373,498
Ensembl chr15:101,360,094...101,373,526
|
|
G |
ID2 |
inhibitor of DNA binding 2 |
decreases expression |
EXP |
ochratoxin A results in decreased expression of ID2 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 3:127,500,759...127,503,207
Ensembl chr 3:127,500,763...127,503,257
|
|
G |
IGFBP2 |
insulin like growth factor binding protein 2 |
increases expression |
EXP |
ochratoxin A results in increased expression of IGFBP2 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr15:118,822,092...118,850,985
Ensembl chr15:118,822,047...118,850,976
|
|
G |
IL18 |
interleukin 18 |
increases expression |
EXP |
ochratoxin A results in increased expression of IL18 protein |
CTD |
PMID:36281498 |
|
NCBI chr 9:39,839,959...39,861,258
Ensembl chr 9:39,834,973...39,861,219
|
|
G |
IL1A |
interleukin 1 alpha |
multiple interactions |
EXP |
ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]] |
CTD |
PMID:28528741 |
|
NCBI chr 3:43,718,320...43,731,668
Ensembl chr 3:43,718,368...43,731,119
|
|
G |
IL2 |
interleukin 2 |
decreases secretion |
EXP |
ochratoxin A results in decreased secretion of IL2 protein |
CTD |
PMID:28699257 |
|
NCBI chr 8:101,640,938...101,645,683
Ensembl chr 8:101,640,944...101,645,609
|
|
G |
IL4 |
interleukin 4 |
increases expression |
EXP |
ochratoxin A results in increased expression of IL4 mRNA |
CTD |
PMID:14994279 |
|
NCBI chr 2:134,986,817...134,994,365
Ensembl chr 2:134,986,817...134,994,365
|
|
G |
IL6 |
interleukin 6 |
increases expression multiple interactions |
EXP |
ochratoxin A results in increased expression of IL6 mRNA NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of IL6 mRNA] |
CTD |
PMID:28710020 |
|
NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
|
|
G |
JAK2 |
Janus kinase 2 |
multiple interactions increases phosphorylation |
EXP |
Decitabine inhibits the reaction [ochratoxin A results in increased phosphorylation of JAK2 protein] |
CTD |
PMID:30923867 |
|
NCBI chr 1:216,849,744...217,002,310
Ensembl chr 1:216,848,689...217,002,148
|
|
G |
LCN2 |
lipocalin 2 |
multiple interactions |
EXP |
[fumonisin B1 co-treated with ochratoxin |